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ALLGEMEINE ZUSAMMENFASSUNG 
Der Typ 3 Sekretionsapparat ist eine molekulare Maschine, die in zahlreichen 
bakteriellen Krankheitserregern nachgewiesen wurde. Es handelt sich um einen 
Proteinkomplex in der bakteriellen Membran, der in einem gerichteten Prozess 
Toxine vom Bakterium in das Zytoplasma einer Wirtszelle transportiert. Er 
ermöglicht dadurch zahlreiche Strategien, welche die Infektion des Wirtes und 
komplexe Überlebensstrategien des Bakteriums erlauben. Die Erreger von 
bedeutenden Krankheiten wie Pest, Typhus oder Bakterienruhr bedienen sich dieses 
Mechanismus.  
Das bisher am besten untersuchte Merkmal des Sekretionsapparates ist der so 
genannte Nadelkomplex. Er ähnelt äußerlich und funktionell einer Spritze, und 
erstreckt sich mit einer in der inneren und äußeren Membran verankerten Basis, die 
das Periplasma quert, und einer extrazellulären Nadelstruktur über etwa 80 nm. Der 
maximale Durchmesser der unregelmäßig zylindrischen Struktur beträgt etwa 21 nm. 
Der gesamte Sekretionsapparat besteht aus mehr als zwanzig Proteinen, bisher 
konnten fünf strukturelle Proteine im Nadelkomplex nachgewiesen und teilweise 
lokalisiert werden. 
Der Aufbau des Komplexes erfolgt schrittweise und ist von der Sekretion 
spezifischer struktureller Proteine in aufeinander folgenden Stadien geprägt. Dies 
wird durch einen Wechsel im Erkennungsmuster der sekretierten Proteine erreicht. 
Nach Abschluss des Aufbaus wiederholt sich dieses Phänomen in Form der 
gestaffelten Sekretion von Effektorproteinen, welche im fortschreitenden 
Krankheitsverlauf unterschiedliche Funktionen erfüllen. 
In dieser Studie wurde das Protein PrgH, ein Bestandteil des Nadelkomplexes im 
Humanpathogen Salmonella typhimurium, untersucht. Anfängliche elektronen-
mikroskopische Untersuchungen zielten darauf ab, das Protein mittels exakt 
lokalisierter Goldpartikel im Komplex zu markieren, im weiteren Verlauf wurde die 
Rolle von PrgH im Sekretionsprozess näher analysiert. Mittels genetischer Methoden 
wurde eine Bibliothek von Mutanten generiert, deren Phänotyp hinsichtlich 
erfolgreichem Aufbaus des Nadelkomplexes und dessen Sekretionsaktivität 
biochemisch untersucht wurde.  
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Die erhalten Daten zeigen, dass PrgH den äußeren Bereich des inneren Ringes des 
Nadelkomplexes aufbaut, und seine N-terminale Domäne in das Zytoplasma 
ausgerichtet ist. Durch die Untersuchung der Mutanten wurde mehrere Bereiche von 
PrgH identifiziert, welche eine kritische Rolle in der Sekretion von Effektorproteinen 
spielen.  
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ABSTRACT 
Type 3 secretion systems are conserved molecular machines commonly found in 
Gram-negative bacterial pathogens, such as Salmonella, Shigella, Yersinia or 
enteropathogenic Escherichia coli (EPEC), and play essential roles in the 
development of the diseases typhoid fever, dysentery or bubonic plaque, among 
others. In these organisms, at least one pathogenicity island encodes this highly 
evolved secretion apparatus, which allows bacteria to modify host cell behavior in 
order to allow efficient infection and long-term survival.  
The large core structure of the type 3 secretion system is commonly referred to as the 
needle complex. It consists of at least five proteins with varying copy numbers, 
assembling into a syringe-shaped configuration, which allows directed transport of 
proteins from the bacterial cytoplasm to a host cell. Assembly of the complex 
happens stepwise, with specific structural proteins being secreted per stage of the 
assembly process. Similarly, effector proteins are secreted in a hierarchical fashion 
tailored to their role in the pathogenicity process. 
Despite the importance of type 3 secretion systems, the topology of the needle 
complex and the structural basis for substrate recognition is poorly understood. Here, 
Salmonella typhimurium was used as a model organism to study the localization of 
PrgH and its relevance to the assembly and secretion process.  
Using electron microscopy and site-specific labeling methods, PrgH was found to 
compose the outer areas of the inner ring, with the N-terminal domain located 
towards the cytoplasm. By screening a library containing mutated variants of PrgH 
using two novel ELISAs to assess successful assembly and secretion activity, the N-
terminal domain was found to contain areas critical for the secretion of the effector 
protein SptP. Interestingly, secretion of the pore-forming proteins SipB and SipC was 
less affected, suggesting that PrgH is involved in the substrate switching process 
between pore-forming proteins and effector proteins, or early and late effector 
proteins.  
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INTRODUCTION 
The co-evolution of pathogenic bacteria and their hosts has led to a number of 
remarkable adaptations. Several species of Gram-negative bacteria [1] use a complex 
molecular machine to induce changes in the behavior of eukaryotic host cells to aid 
their own survival and proliferation. This so-called type three secretion system 
consists of a syringe-like structure in the bacterial membrane (needle complex, 
injectisome), a cytoplasmic bulb (c-ring) and a number of effector proteins. By 
creating a secure transport pathway from the bacterial cytoplasm through two 
bacterial membranes into the cytoplasm of a neighboring host cell, they open a 
directed communication channel, through which effector proteins are transported in 
an orchestrated manner [2]. The courses of diseases caused by human or plant 
pathogens such as Salmonella, Yersinia, Chlamydia, Pseudomonas, or Erwinia are 
thereby critically influenced by this pathogenicity factor. 
A model pathogen: Salmonella enterica 
Salmonella enterica strains are enteric pathogens causing a variety of diseases, 
ranging in severity from typhoid fever to gastroenteritis. Both serovar typhi (S. typhi) 
and serovar typhimurium (S. typhimurium) contain several pathogenicity islands, 
although only S. typhi can cause systemic infections in human. Infection with S. 
typhimurium causes a usually relatively benign gastroenteritis in humans. In contrast 
to S. typhi it can also infect a wide range of animals, including mice, where it causes 
systemic infection similar to typhoid fever in humans.  
Even before the complete sequence of Salmonella enterica serovar Typhimurium LT2 
had been available [3], five pathogenicity-associated loci had been identified using 
genetic techniques and screening methods [4]. They have been termed salmonella 
pathogenicity islands (SPIs), with a sixth added more recently [5]. 
SPI-1 and SPI-2 each encode a fully functional type three secretion system. SPI-1 
stretches over roughly 40kb and contains at least 29 genes, used for the regulation 
and expression of proteins constituting a functional type three secretion system. SPI-
1 and 2 are structurally and functionally distinct, and show homology to different 
archetypes [6]. SPI-1 is involved in the invasion of endothelial cells of the small 
intestine, by injecting effector proteins through the needle complex into the 
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neighboring host cell, thereby causing disturbances in the actin cytoskeleton. SPI-2 
genes are quickly upregulated after bacterial entry into endothelial cells or 
macrophages and stay active during the course of infection. Its function has been 
linked to extended survival within macrophages in mouse models. While SPI-1 was 
described as necessary for bacterial invasion in 1989 [7, 8], SPI-2 was only found 
and characterized six years later [9-11]. 
General structure of the SPI-1 injectisome 
Since the first visualization of a needle complex on the surface of salmonella cells 
[12], reconstructions of the three dimensional structure of the basal body or the entire 
needle complex [13-17] were obtained from S. typhimurium, Shigella flexneri and 
enteropathogenic Escherichia coli. The overall structure appears to be conserved [6], 
and consists of a generally cylindrical complex with distinct inner and outer rings 
(see Figure 1) and a maximum diameter of approximately 21 nm [15]. In S. 
typhimurium, the major structural proteins are InvG in the outer ring, belonging to 
the secretin family, with PrgH and PrgK in the inner ring.  
 
 
Figure 1: (A) Purified needle complexes (B) Map of the needle complex 
 
The radial symmetry is still under debate, with proposed values ranging from 12-fold 
upwards, limiting the usefulness of proposed topology models [13, 14, 18]. The 
needle filament is extending outwards from the basal body, a helical structure 
polymerizing from PrgI subunits [19]. Within the basal structure, a so-called inner 
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rod, a cup and a socket region have been identified. Strains lacking InvJ are deficient 
for the socket region, while PrgJ has been suggested to form the inner rod [14]. 
Additionally, strains lacking any of the proteins OrgA, OrgB or several Spa-proteins 
[20] successfully form the basal body, but fail to assemble the needle filament. As of 
now, the functional role of most of these proteins is unclear, although SpaP, Q, R and 
SpaS are expected to localize within the inner ring, based on homologies to the 
flagellar system [21]. 
The ATPase InvC is said to energize the secretion process and might connect to the 
basal body through homologs of the c-ring proteins [6]. It could already be shown 
that InvC is required to release effector proteins from their cognate chaperones [22, 
23]. In this unfolded state, the proteins would then be able to pass through the central 
pore, with an estimated width of 2.5 nm. 
Assembly of the injectisome 
Similar to the flagellar system, assembly of the needle complex is considered a 
strictly linear process [6]. Membrane insertions of PrgK and InvG are dependent on 
the general secretory pathway (Sec), while other components of the needle complex 
are secreted by themselves in a highly regulated fashion, suggesting the existence of 
several checkpoints and changes in the specificity for secretion substrates. As 
proposed here [2], two switching events occur during the assembly process. The first 
would occur once the needle filament reaches its full length, the second one on cell 
contact, if the translocators are in place (Figure 2). 
InfJ, PrgJ and PrgI are usually considered early substrates, are secreted through the 
basal body and polymerize to form the socket region, the inner rod and the needle 
filament, respectively. In S. typhimurium, needle length control was described to 
depend on the relative amounts of PrgI and PrgJ [14]. C-ring related proteins and 
InvC-deficient strains are unable to form the needle filament [20], suggesting 
recruitment before secretion of the first substrates takes place. 
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Figure 2: Illustration showing assembly of the needle complex, with substrate 
switching after PrgI/J and SipD/B/C. (A) Assembly of the needle complex (B) 
Secretion of translocators and assembly of tip complex/pore (C) Secretion of effector 
proteins [6, 19, 24] 
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Once the needle filament is assembled, the middle substrates, translocator proteins 
SipB, SipC and SipD are targeted to the complex, creating a secretion-blocked 
“stand-by” situation in Yersinia and Shigella [2]. Once a host cell is detected, 
possibly by the tip structure, a pore can be formed in the host cell membrane and 
protein translocation [2, 25] can occur. 
Effector proteins of SPI-1 
While S. typhimurium shows secretion of effector proteins to the culture supernatant 
without cell contact, the start of secretion is highly regulated in other organisms [6]. 
SipA, SopB, SopE, SipE as well as AvrA and SptP among other effector proteins are 
transported through the needle complex. Using fluorescence microscopy, the process 
could be visualized and appeared to take place within less than 10 minutes after cell 
contact [26]. 
Their combined effect is a drastic, although temporary, reshaping of the host cell 
membrane (ruffling) at the contact point between endothelial cell and bacterium, 
followed by internalization of the bacterium. While early effector proteins induce 
membrane ruffling and promote bacterial engulfment, late effector proteins reverse 
these effects and allow the cell to regain its original shape. A distinct hierarchy has to 
exist in the secretion of effectors through the type three secretion system of S. 
typhimurium, to avoid the presence of effector proteins with antagonizing effects in 
the host cell at the same time [27, 28]. 
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Research questions 
In order to better understand the role of proteins suspected to lie at the interface 
between the needle complex and cytoplasmic components of the type three secretion 
system, different lines of research were followed to answer the following questions: 
 
What is the exact localization and organization of PrgH and PrgK, and can they 
be directly visualized using site-specific labels? 
Is PrgH purely a scaffolding component of the needle complex, or is it directly 
interacting with cytoplasmic or membrane associated proteins beyond the core 
complex? 
 
Site specific labeling 
Mapping the subunits of an intricate protein assembly as the needle complex is 
challenging. While the structure can by now be routinely imaged at low resolution, 
the identification and localization of distinct subunits would require ideally near-
atomic resolution. While this goal can in principle be achieved based on electron 
microscopy data alone [29], no structure of the type three secretion system with a 
sufficiently high resolution has so far been published.  
By using x-ray crystallography, protein structures are routinely solved at atomic 
resolutions, although the process becomes more complex with increasing size of the 
target. While large assemblies over 1 megadalton (MDa) in size are now in reach of 
the technique [30], smaller structures are more readily available.  
The strengths of both techniques can be combined when high resolution structural 
data of subunits is used to reconstruct the overall topology within a global, low 
resolution map. This modeling process depends on the availability of restraints in 
order to position individual subunits with a high degree of confidence. Restraints are 
derived from multiple sources, including molecular modeling, information on the 
copy number or quaternary structures of subunits or anchor points created by 
identifying the subunit on the overall structure. 
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Since atomic structures of several core proteins, or domains of core proteins, became 
available, a number of incompatible models for the topology of the needle complex 
were proposed [13, 18]. In this study, polyhistidine tags in multiple positions on the 
protein complex were used as site-specific binding partners for 1.4 nm small Ni-NTA 
gold particles. When a gold particle is bound to a needle complex, it can be 
recognized as an additional electron density on electron micrographs. Particles of this 
size offer an acceptable compromise between ease of visualization, and accuracy of 
the localization. 
 Screening for functional domains 
PrgH (392 amino acids) is a predicted transmembrane protein located in the inner 
ring of the needle complex, with at least two separate domains in the periplasmic and 
the cytoplasmic space. It is essential for and recruited early [20, 31] in the assembly 
process of the needle complex, suggesting a potential scaffolding role for later 
assembly steps. Additionally, the cytoplasmic domain could represent an interaction 
site for secretion substrates.  
No information on the role of PrgH in either the assembly process, or the secretion 
process was available so far. The experimental setup therefore aimed to create a 
library with mutation sufficient to disrupt structural elements, and screen these 
mutants for failures in the assembly process and the ability to secrete proteins. 
The generation of mutant forms a protein in order to understand its function is a 
common approach. Between removing large parts of a protein, to substituting 
individual amino acids, a wide range of commonly used strategies exists. The 
decision for a specific type of mutagenesis must therefore be carefully matched to the 
situation at hand, weighing the information gained from more subtle mutations 
against the complexity of dealing with an increasing number of constructs. 
By creating extensive deletion mutants [32], the entire sequence can be covered with 
few constructs. The limited number of strains can then be screened for changes in the 
phenotype using even elaborate manual methods. The resulting map of the protein 
will necessarily be coarse, but drastic changes in the protein architecture can be 
expected and understood. 
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On the other extreme end, the creation of an exhaustive library of single amino acid 
substitutions will usually require hundreds or thousands of mutated variants screened 
for potentially subtle changes in the phenotype, prohibiting the use of complex or 
manual screening methods [23]. If suitable screening or selection methods are 
available, the resulting data set can offer a very detailed view on the functional 
relevance of small parts of the protein. 
In this study, a transposon-based mutagenesis kit was used to create a library of PrgH 
variants, each containing an insert of five amino acids. A mutation of this size will in 
most cases not alter the tertiary structure drastically, but will readily disrupt 
secondary structures and possibly affect other interaction sites.  
The number of strains to achieve full coverage was estimated at around 80. While it 
would be possible to perform traditional secretion assays on this scale, imaging all 
strains by electron microscopy to identify phenotypes relevant to the assembly 
process would be extremely time consuming. To avoid this bottle neck, two ELISA-
based assay methods were established. 
In a typical ELISA, a target molecule is fished from a sample and bound to the 
reaction chamber by antibodies. In sequential steps the fixed molecule is then bound 
by a primary antibody, which is recognized by an enzyme-coupled secondary 
antibody. The enzyme facilitates conversion of a specific substrate into a detectable 
product, with the speed of the reaction being dependent upon the amount of bound 
target molecules.  
 
 
Figure 3: Schematics for (A) Structure ELISA and (B) Secretion ELISA 
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Overall, the first two binding steps act as selectivity filters, while the catalytic 
activity of the enzyme allows amplification of even weak signals stemming from 
minute concentrations of the target molecule. The methods described here are 
variations on this concept.  
The structure ELISA (StrucELISA, Figure 3A) takes advantage of the sequential 
assembly of the needle complex. By binding the primary inner ring subunit PrgH 
with a polyhistidine tag to Ni-groups on the multiwell plate, detection of other, later 
added subunits becomes a possibility. Here, the needle filament subunit, PrgI, was 
detected. As this is the last structure formed during the assembly process, it serves as 
a marker for the presence of completely assembled needle complexes.  
For the secretion ELISA (SecELISA, Figure 3B), chaperones with high binding 
affinities are used instead of a capturing antibody to bind corresponding effector 
proteins. By using two highly selective binding steps, effector proteins could be 
detected directly from the culture supernatant. 
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METHODS 
DNA work 
Plasmids were constructed using standard laboratory procedures. Kits routinely used 
for DNA purification and extraction include the QIAquick® PCR Purification Kit, 
Nucleotide Removal Kit, Gel Extraction Kit,QIAprep® Miniprep and QIAfilter® 
Maxiprep Kit, all used according to the manufacturers instructions.  
Polymerase chain reactions (PCR) were performed using Pfu or Pfu turbo 
polymerase (Fermentas, USA) according to the supplied manual and with the set of 
primers listed for each plasmid. Restriction enzymes were obtained from Fermentas 
(USA) or New England Biolabs (USA) used in combination with their respective 
buffers and under the recommended reaction conditions. Dephosphorylation of DNA 
fragments was performed using calf intestinal alkaline phosphatase (CIAP), to 
promote formation of specific ligation products.  
All constructs could either be created through attaching restriction sites at both ends 
of an insert or by fusing two primary PCR fragments with overlapping ends in a 
second PCR step ([33], p.208). The resulting fragment could then be digested with 
the appropriate restriction enzymes and ligated into the target plasmid. The second 
technique offered advantages when fusing the upstream promoter region to a 
construct without inserting a restriction site in between, while avoiding the use of 
inefficient blunt end ligation.  
If a large number of base pairs had to be attached to a protein, multiple PCR steps 
were used, each using the prior product as a template and a primer binding to the 
newly created overhang. 
Plasmids and DNA fragments were visualized by electrophoresis (90 V) in 1% 
agarose gels, prepared in Tris-acetate buffer with EDTA (TAE buffer), stained with 
Sybr® green dye. Images were taken using BioRads Universal Hood II and the 
Quantity One / Gel Doc XR software package. Finished constructs were routinely 
sequenced by the in-house service department and analyzed using 4peaks 
(mekentsoj.com) and DNAman (Lynnon Corp.).  
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Transformation of DH5α cells 
Amplification of plasmids was done by transformation in Escherichia coli (E. coli) 
DH5α cells. Heat shock competent cells were supplied by the in-house service 
department and stored at -80°C. 150 µl of these cells were thawed on ice for 10 
minutes, up to 100 ng of DNA were added and carefully mixed. After keeping the 
mixture on ice for 30 minutes, cells were heat shocked for 30 seconds and left to 
recover on ice for 5 minutes. 950 µl room temperature SOC medium were added and 
the cells grown at 37°C with strong shaking for at least 60 minutes. 10 – 200 µl were 
plated on pre-warmed LB agar plates with necessary antibiotics. Colonies could be 
picked after growth over night. 
For blunt end cloning of PCR fragments into a SmaI-digested bluescript vector 
(pBSK II+, Stratagene, USA), samples were ligated over night at 20°C, 40 µl XGal 
and 40 µl Isopropyl-β-D-thiogalactopyranosid (IPTG) [34] were spread an hour 
before plating the cells. Blue colonies indicated no insert, while white colonies 
contained plasmids with ligated inserts. 
Transformation of Salmonella typhimurium 
To achieve higher transformation rates, Salmonella strains were routinely 
transformed by electroporation. The following protocol describes both the 
preparation of electrocompetent cells and the transformation itself. 
100 ml of LB liquid culture with suitable antibiotics were inoculated and the culture 
grown over night at 37°C and 220 rpm. On the following morning this pre-culture 
could be diluted in 1000 ml LB medium plus suitable antibiotics, and grown at 37°C 
and 180 rpm to an OD600 of 0.5 – 0.7. The culture was cooled down quickly in ice 
cold water for up to 30 minutes and harvested in a cooled centrifuge (4250g, 15 min, 
4°C, Beckmann Coulter Avanti J26-XP, rotor JLA 9.100, 7250 k-factor). The cells 
needed to be resuspended in 500 ml of 4°C cold sterilized water, and pelleted again. 
This washing step was repeated an additional time with 200 ml of cold water (200 
ml), followed by washing with 10% cold glycerol, first 200 ml, then 30 ml. An 
additional washing step was done in 50 ml falcon tubes (rotor #3057, Multifuge 3SR, 
Heraeus, UK), after which the cells were resuspended in 1 ml 10% glycerol, 
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aliquoted (80 µl each) and stored at -80°C. Fresh cells could be kept on ice and 
offered higher transformation efficiency than frozen cells. The initial culture and the 
subsequent washing steps could be scaled up or down, depending on the number of 
aliquots required. 
The electroporation was done using 80 µl of frozen cells with 50-200 ng of DNA, 
filled up to 100 µl total volume with cold water. To optimize transformation rates, 
the volume of the added DNA solution was kept as small as possible. Minimizing the 
salt concentration in the samples gave higher transformation rates, therefor DNA for 
electroporation was eluted in water instead of the supplied elution buffer. All 
electroporation equipment (cuvette and holder) was cooled to 4°C. 
Using a 2510 electroporator (Eppendorf, USA) and cuvettes with 0.1 cm distance 
between electrodes, the voltage was set to 1800 V. Directly following 
electroporation, 900 µl of SOC medium were added to the cuvette, and the cell 
suspension transferred into a 1.5 ml tube. Good recovery rates were achieved by 
growing the cells for 60 minutes at 37°C at 650 rpm in a thermo mixer (Eppendorf, 
USA). Longer recovery times of up to 120 minutes were used if the transformed 
plasmid contained a chloramphenicol acetyltransferase (CAT) resistance marker. 
If a sufficient amount of DNA was used, plating 200 µl of the mixture on a LB plate 
with suitable selection markers was sufficient to obtain 20 to 100 separate colonies. 
If the amount of DNA was low, all cells were pelleted, resuspended in 100 µl LB 
medium and spread on a agar plate. Plates incubated at 37°C usually displayed at 
least small visible colonies over night.  
Linker Scanner Mutagenesis 
Purified target plasmid (pWS006) was subjected to the GPS-LS reaction using the 
supplied pGPS5 plasmid (Kanr) as donor, transformed into commercial highly 
efficient E. coli cells (NEB, US ) and grown on LB agar plates with kanamycin and 
ampicillin, selecting target plasmids with transprimer insertions. In order to archive a 
suitable coverage several thousand individual colonies were calculated to be 
necessary. Colony numbers on several plates were estimated and pooled by scraping 
them from a plate. This pool of cells was grown for shortly at 37°C, followed by 
DNA extraction. To remove plasmids with insertions in the backbone, the promoter-
PrgH insert was cut out and religated into pwsk29. The resulting plasmid library was 
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again transformed into commercial highly efficient E. coli cells (NEB, US), grown 
on LB agar plates under selection, pooled and the DNA extracted. To remove the 1.7 
kb transprimer insertion carrying Kanr, the plasmid pool was digested with PmeI and 
religated, resulting in a pool of plasmids carrying 15 bp insertions only in PrgH and 
the upstream promoter (Figure 4). 
This library was transformed into commercial highly efficient E. coli cells (NEB, 
US), about 1200 single colonies were picked, grown and the insert sequenced using a 
set of three primers. The resulting dataset was analyzed using a custom set of tools 
provided by the IMBA/IMP bioinformatics department, which automatically aligned 
multiple sequencing runs and annotated the insert. A set of plasmids carrying well 
distributed mutations all over PrgH was put together. Insertions resulting in a new 
stop codon, plasmids carrying more than one mutation or mutations in the promoter 
region were not considered. The final 87 plasmids (“original”) were transformed into 
∆prgH-Salmonella (SB906+pHilA(Cmr) and screened for the presence of needle 
complex and secretion activity using the StrucELISA and SecELISA protocols. Each 
strain was tested at least three times from independently grown cultures.  
To confirm both the sequence, the structural and secretion data, the 87 plasmids were 
transformed separately into DH5α cells, the DNA extracted and sequenced again. 
Glycerol stocks of these strains were stored at -80°C. The plasmids (“control”) were 
also transformed into SB906+pHilA(Cmr) again, and tested for the presence of 
structure and secretion activity. During these additional confirmation experiments, a 
number of strains was identified that contained stop codons or redundant inserts, 
leaving 75 independent strains for analysis. 
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Figure 4: Workflow for creating a library of mutants based on the GPS™-LS 
Linker Scanning Mutagenesis Kit. 
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Standard needle complex purification 
The commonly referred to preparation of a needle complex involves three major 
sections. First a growth period, in which formation of the needle complex by a 
bacterial strain is encouraged. Secondly, a lysis step that aims at gently dissociating 
the needle complex from the bacterial membranes it is embedded in. Lastly, a series 
of purification steps, ranging from isopycnic and isokinetic ultracentrifugation to 
pelleting steps, is necessary in order to obtain a sufficiently pure and dispersed 
sample. The original protocol [14] was modified by Oliver Schraidt, and further 
adapted as necessary. 
The yield of a needle preparation depended to a large extent on the modifications 
imposed upon the proteins (tags, etc) making up the needle complex. For the 
salmonella strain SB905 (considered wild-type), with HilA-based expression 
amplification, 1 liter of culture gave a fairly large number of complexes, easily 
sufficient for most imaging purposes. The yield of other strains with modified needle 
complexes could be drastically reduced, requiring culture volumes of 10 liters and 
beyond. Even though the protocol here states 1 liter culture volume, the lysis 
protocol was successfully applied to bacterial cultures of 3 liters with a final OD600 
of about 1.8. This appeared to be sufficient for most purposes. If an even larger 
culture was required, the lysis volume could be scaled up accordingly. 
A 200 ml preculture of the required strain was grown over night in liquid LB 
medium, with 300 mM NaCl and the appropriate antibiotics, here commonly 
ampicillin (AMP, 100 mg/ml), chloramphenicol (CMP, 25 mg/ml) and/or kanamycin 
(KAN, 20 mg/ml). The incubator was set to 37°C and 220 rpm, 2 liter Erlenmeyer 
flasks were used. 
On the following morning, the preculture was diluted to an OD600 of 0.1 to 0.3 with 1 
liter of preheated (37°C) LB medium, containing 300 mM NaCl. The resulting 
culture was split up into 500-600ml aliquots and transferred to 2 liter culture flasks, 
to be incubated at 37°C and 180 rpm. Antibiotics could be used for stringent 
selection, but prolonged the growth phase and draw out the entire protocol.  
Once the culture reached an OD600 of about 0.5, induction of HilA expression using 
the pSB667 or pSB1418 plasmid took place by adding arabinose to a final 
concentration of 0,012% (0,3 ml 20% arabinose solution per 500ml). 4.5 to 5 hours 
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after induction the culture reached stationary phase and the fully formed needle 
complex was present on the cells surface. Recording a growth curve allowed 
following the maturation of the culture and is recommended. Most strains used for 
this thesis reached a final OD600 of 1.5 to 1.8, depending on the OD600 at the time of 
induction.  
If a culture was harvested prematurely, e.g. after 3 to 3.5 hours, a larger portion of 
the isolated needle complexes displayed shorter needles or no needle filament at all. 
Cells were harvested by centrifugation at 4250g for 15 min (Beckmann Coulter 
Avanti J26-XP, rotor JLA 9.100, 11410 k-factor) and the supernatant discarded.  
The lysis procedure started by resuspending the cell pellet in 100 ml 0.5M sucrose 
and 0.15M Tris buffer at pH 8.0. Ions were chelated by adding 2.5 ml 0.5 M EDTA 
solution. 5 ml lysozyme solution (30 mg/ml, 98381 IU/mg) were added, and the 
suspension slowly stirred on ice for 30 to 60 minutes. Afterwards, a protease 
inhibitor was added (Complete® Protease Inhibitor, 1 tablet) and the temperature 
raised to 37°C by placing the flask in a water bath for 15 to 30 minutes. After adding 
4 to 5 ml 10% Lauryldimethylamine-oxide (LDAO), the viscosity of the solution 
increased. Adding 11 ml of 5 M NaCl cleared the solution, and 2 ml 1 M MgCl2 
reactivated DNAses, liquefying the solution within 5 to 10 minutes. After this, the 
sample had to be put on ice again and could be stirred for 30 to 60 minutes. 
The first centrifugation (Beckmann Coulter Avanti J26-XP, 250ml tubes, rotor JLA-
16.250; 9000g, 20min, 4°C; 1400 k-factor) helped to clear large cell debris from the 
solution. Dhe pellet was discarded and the supernatant split into equal parts for the 
following ultracentrifugation. In this step, the needle complex and similar structures 
were pelleted (Beckman UC, 70ml PC tubes, rotor Ti 45; 40000 rpm, 150 min, 4°C, 
168.1 k-factor). The supernatant could be discarded, the pellet needed to be carefully 
resuspended in 2 or 4 ml of resuspension buffer 1 (10mM Tris, 0.5M NaCl, , 0.5% 
LDAO, pH 8.0). The use of pipet tips with a wide opening worked well to reduce 
mechanical stress. After careful rinsing of the wall above and the pellet itself, the 
sample was placed on a shaker for 60 minutes. A slow shaking setting was used to 
avoid the formation of foam. 
For the subsequent isopycnic centrifugation, cesiumchloride (CsCl) was added to the 
resuspended sample. A stock solution of 52,5% CsCl in resuspension buffer 1 was 
prepared. 4 ml of 52,5% CsCl solution were added to 200 µl 10% LDAO and 3.8 ml 
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of resuspended sample, resulting in a final concentration of 27,5% CsCl. The 
gradient formed during ultracentrifugation over night (Sorvall 90SE, rotor TH-660, 
50 krpm, 12 to 15 h, 5°C), maximum acceleration, minimal deceleration, 64 k-factor) 
in 4.4 ml PA thinwall tubes (Thermo Scientific, US). 
If 6 fractions of 660 µl each were taken using tips with wide openings, membranes 
and byproducts were found in fraction 1, complexes without needle filaments were 
found in fraction 2, while fully formed needle complexes were located in fraction 3 
and 4, if counted from the top. To check for the presence of the needle complex, see 
the imaging protocol. 
Fractions containing the desired structure were pooled. To remove the CsCl, the 
sample was diluted with resuspension buffer 2 (10mM Tris, 0.5M NaCl, , 0.1% 
LDAO, pH 8.0) and pelleted. 1.2 ml sample were filled up with 1.7 ml of 
resuspension buffer 2, then centrifuged (Sorvall RC M150 GX, rotor S100-AT4-463, 
90000 rpm, 30min, 5°C, 19.7 k-factor) in 3 ml polycarbonate thickwall tubes 
(Hitachi Koki, JP). The pellet was resuspended in 70 to 100 µl of resuspension buffer 
2, again care was taken to avoid the formation of foam. The wall of the tube was 
carefully rinsed (~10x) and the pellet itself gently resuspended. The tube was slowly 
shaken for 30 minutes and the amount of needle complex determined using the 
electron microscope. 
To further purify the sample and to remove needle complex aggregates, an isokinetic 
centrifugation was used. The necessary continuous 10-25% sucrose gradient was 
prepared on a linear gradient maker. Both the 10% and 25% sucrose solution (10 mM 
Tris or PBS based buffer, 500 mM NaCl, 5 mM EDTA, 0,1% LDAO) was diluted 
from a 50% stock solution at room temperature, LDAO was freshly added. A 4.4 ml 
PA thinwall tube (Thermo Scientific, US) was marked using the measuring device 
belonging to the gradient mixer and filled up to this mark with 10% sucrose solution. 
The 25% solution was added from below with a spinal needle, to create two 
distinctly separated layers, which fill the tube completely. The short plug was put on 
the tube without enclosing any air, and the tube rotated using the “10-25% short” 
program. 
The finished gradient was cooled to 4°C for 15 minutes, the plug taken off and up to 
150 µl of sample were applied on top. After the centrifugation (Sorvall 90SE, rotor 
TH-660. 50,000rpm, 4°C, 210 min, 64,5 k-factor) fractions were taken. If fractions 
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of 2x1.1 ml and 4x 450µl are taken from top, wild type needle complexes were 
usually located in fractions 3 to 5.  
The chosen fractions could be pooled and diluted with suitable resuspension buffer 
(10mM Tris or PBS, 0,5M NaCl, 5mM EDTA, 0,1% LDAO, pH 8) and pelleted 
(Sorvall RC M150 GX, rotor S100-AT4-463, 90000 rpm, 30min, 5°C, 19.7 k-factor) 
in 3 ml polycarbonate thickwall tubes (Hitachi Koki, JP). Resuspending the sample 
was done using tips with a wide opening in resuspension buffer 3, or other suitable 
buffers as required. 
The presence of a polyhistidine tag on a needle complex tended to lead to aggregated 
samples, which could be counteracted by the addition of Imidazol (20mM final 
concentration) and ethylenediaminetetraacetic acid (EDTA, 20mM final 
concentration) both after the lysis step, and in the resuspension buffers used during 
subsequent steps. No structural changes were observed due to treatment with EDTA 
or Imidazol at this concentration and within the period of time necessary to complete 
the purification.  
Two different buffers were commonly used for storing the final sample. For day-to-
day imaging, buffers based on tris(hydroxymethyl)aminomethane (TRIS) were used. 
If a specific labeling reaction impeded the use of TRIS, posphate buffered saline 
(PBS) buffers were a suitable alternative. For complete removal of TRIS, the change 
of buffers happened with the resuspension step after the CsCl-gradient, and all 
subsequent buffers had to be changed to PBS as well.  
Ni-NTA-NanoGold® labelling of polyhistidine tags 
Purified needle complex was incubated with with 1 mM N-ethylmaleimide at 4 °C 
over night to block free thiols and to prevent unspecific NanoGold interactions with 
cysteine residues. To further suppress unspecific labelling, imidazol was added (20 
mM). Incubation with 5 µM nickel-nitrilotriacetic acid (Ni2+-NTA) NanoGold 
(Nanoprobes, USA) at room temperature for 10 minutes lead to binding of the gold 
label. The resulting sample was separated from unbound Ni-NTA-NanoGold 
particles by gel filtration (Sepharyl 300 column) and used for cry electron imaging 
(Schraidt et al 2010). 
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Long needle filament purification 
Purifying a needle complex with a extended needle filament is taxing, due to the 
sheer size of the complex and the relative sensitivity regarding shear forces. The 
protocol described here is a heavily modified version of a normal needle complex 
preparation, with a focus on avoiding pelleting and resuspending steps, and gradient 
concentrations adapted to the density of the needle filament. The primary growth 
period needed to be extended to allow full formation of the filament, whereas the 
lysis could proceed according to standard procedures.  
The purification steps were adapted to avoid the preclearing step, although the exact 
consequences of this decision were not tested. Additionally, two CsCl gradient 
centrifugation were performed, one being a short CsCl cushion to gently move the 
NC out of the lysed sample while keeping cell debris afloat, and a second one over 
night to remove additional impurities, followed by a single pelleting and 
resuspension step. 
The protocol here describes a rather large preparation based on 12 liter of culture, 
which will yield an amount of needle complex exceeding more than sufficient for 
standard imaging procedures. 
 
A swab from a glycerol stock was diluted in 10 ml of LB medium 10 minutes before 
the inoculation. 12 liter of 4°C cold LB liquid medium (LB, 0.3 M NaCl, suitable 
antibiotics, 0,02% Arabinose) were split into 22 2 liter culture flasks, containing 600 
ml each, and were inoculated with the preculture. Cells were allowed to grow over 
night (37°C, 180 rpm), the culture was stopped when the OD600 reached 1.5, usually 
after 17-18 hours. The lysis protocol is similar to the normal preparation, but using 
three times as much volume. 
Cells were harvested by centrifugation at 4250g for 15 min (Beckmann Coulter 
Avanti J26-XP, rotor JLA 9.100, 11410 k-factor) and the the supernatant discarded.  
Cell pellets were resuspended in 300 ml 0.5 M sucrose and 0.15 M Tris buffer at 
pH 8.0. Ions were chelated by adding 7.5 ml 0.5 M EDTA solution, 15 ml lysozyme 
solution (30 mg/ml, 98381 IU/mg) were added, and the suspension was slowly 
stirred on ice for 30 to 60 minutes. Protease inhibitor was dissolved (Complete® 
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Protease Inhibitor, 3 tablets) and the temperature raised to 37°C by placing the flask 
in a water bath for 15 to 30 minutes. After adding 15 ml 10% Lauryldimethylamine-
oxide (LDAO), the viscosity of the solution increased to a honey-like appearance. 
Adding 33 ml of 5 M NaCl cleared the solution, and 9 ml 1 M MgCl2 reactivated 
DNAses, liquefying the solution within 5 to 10 minutes. After this, the sample was 
put on ice again and was stirred for 30 to 60 minutes. 
Western analysis of the preclearing pellet suggested extensive losses of needle 
filament even at slow centrifugation speeds, therefore no preclearing was done here. 
A side effect is a thick layer of cell debris on the subsequent CsCl cushion.  
28 ml aliquots of the lysed cell sample were taken and transferred into 36 ml PA 
tubes (Sorvall centrifuges. US). A 3 ml layer of 36% CsCl solution (36% CsCl in 
10mM Tris, 500mM NaCl, 5mM EDTA, 0.5% LDAO, pH 8) was put under 28 ml of 
sample, using a spinal needle (BD Spinal Needle 18GA 3,50 IN 1,2x90mm). 6 tubes 
were centrifuged at each run, the second batch was stored at 4°C in between. (Sorvall 
Discovery 90SE, rotor AH-629, 28000 rpm, 5°C, 3 hours, k-factor 260k).The 
supernatant was removed down to the floating debris layer, which was then either 
carefully removed or dissected and moved to the side, depending on the texture.  
0.5 ml fractions were taken starting from the bottom and using a spinal needle (BD 
Spinal Needle 18GA 3,50 IN 1,2x90mm) on a 3 ml syringe. 1:30 diluted samples 
were checked for the presence of needle filaments. Those fractions (usually lowest 1-
3 fractions) were pooled. The density of the pooled fractions had to be estimated and 
was adjusted to be above 35%. Here, the lowest 4 fractions were pooled (24 ml total) 
and 2 ml of 60% CsCl stock solution added.  
The sample was split into 6 thinwall tubes (4.4 ml PA, Thermo Scientific, US) and 
centrifuged over night (Sorvall 90SE, rotor TH-660. 40,000rpm
The pellet was resuspended with resuspension buffer (10mM Tris, 0,5M NaCl, 5mM 
EDTA, 0,1% LDAO, pH 8) and appeared to give a high yield, although the filaments 
tended to clump and form rather thick layers. 
, 12h, 5°C, k-factor 
xxxk,. Acceleration 9, Deceleration 0). The needle complexes formed a distinctly 
visible band in the upper third part of the tube. This fraction was taken in as little 
volume as possible and pelleted using small 200µl thickwall tubes (Sorvall RC M150 
GX, rotor S100-AT3, 90 kprm, 30min, 5°C). 
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Alternatively, the sample was resuspended with TE buffer and 0,1% LDAO, which 
gave a far lower concentration of needle filaments as seen on the EM, but with a 
much better distribution and a less obvious tendency to aggregate. TE buffer is 
therefore preferred for preparing samples for imaging purposes. 
Transmission Electron Microscopy (TEM) 
In order to image macromolecular structures using a traditional TEM, the sample 
must be dried, fixed to a sample holder and the contrast enhanced.. The Morgagni 
electron microscope (FEI company, USA) with an 11 megapixel digital camera 
offers sufficient resolution to work on the needle complex, if the sample is coated 
with a heavy metal film by so called “negative staining”. Using the protocols 
outlined below, imaging is possible during all purification steps, ranging from the 
visualization of the needle complex in the cell membrane of intact cells, screening of 
various fractions after centrifugation steps and a final assessment of a purified 
sample. If done properly, the resolving power is sufficient to identify at least large 
structural changes. The necessary protocols are outlined below.  
Ultimately, more advanced sample preparation and imaging techniques are necessary 
to create representations of the needle complex that even allow the unambiguous 
localization of structures less than 2nm in size, such as Nanogold® (Nanoprobes, 
USA). The recently installed FEI Tecnai Polara at 300 kV and a Gatan Ultrascan 
4000 UHS CCD camera open this possibility. Complemented and enhanced by 
automated image acquisition and processing techniques, it is possible to collect a 
dataset sufficient for two-dimensional single particle reconstruction within less than 
a single day, if a high quality sample is supplied. 
In cryo-EM, the sample is embedded in a thin layer of vitreous ice, by freezing in 
liquid ethane, and imaged at low temperatures. This reduces the chemical and 
mechanical stress exerted during negative staining, and avoids deformation of 
complexes by contact and binding to the carbon film or other surfaces.  
The added complexities of working on the Polara cryo-EM prohibited that the work 
was done in person. Plunge-freezing the sample was mostly done in cooperation with 
Oliver Schraidt, who also handled subsequent steps. The relevant protocols are 
outlined in [35] and the thesis of Oliver Schraidt (in preparation). 
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Negative stain EM sample preparation 
Carbon-coated CuPd grids with a 400 µm mesh width were used as supplied by the 
IMP/IMBA electron microscopy service facility.  
Glow discharge 
The surface of a carbon film is modified to improve the distribution of the later 
applied aqueous solution, and to facilitate binding of protein structures to the surface. 
Protocol according to IMP/IMBA Electron Microscopy Service, GR/TM (V1.1, June 
2006). 
Carbon coated grids were placed in batches of 3 to 6 on a glass plate and placed 
between the electrodes of the Bal-Tec SCD 005 sputter coater. Coating was done for 
30 seconds at 21 mA at less than 10 mbar air pressure. Glow discharging a grid had 
to be done directly before applying a sample for negative staining. 
Negative staining 
Protein complexes are bound to a carbon surface, dried und coated with 
phosphotungstic acid, to create a electron-dense layer, that can easily be imaged. 
Protocol according to IMP/IMBA Electron Microscopy Service, GR/TM (V1.0, May 
2007). 
A freshly glow-discharged grid was taken with a forceps at the outer rim and 5 µl 
sufficiently diluted sample were applied for 45 seconds on the carbon-coated side. 
By touching it slightly against filter paper, the liquid sample was taken off. Without 
allowing the grid to dry out, 5 µl of 2% phosphotungstic acid (PTA, filtered, pH 7 
with KOH) were applied, taken off instantly and another 5 µl PTA applied. This 
represents the washing and the coating step. Depending on the thickness of the 
desired stain, PTA was taken off with filter paper from the edge after about 30 
seconds. To avoid salt artifacts, both sides and the forceps had to be thoroughly 
dried. 
When looking for the needle complex in salt-rich buffers (e.g. directly from CsCl-
gradient fractions), dilutions of 1:20 or higher were necessary, and very careful 
removal of all liquid during the first washing step is advisable. Even under these 
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conditions, EM samples prepared directly from gradient fractions generally gave low 
quality results, preventing any quantitative predictions, although still being useful to 
quickly localize relevant fractions without pelleting steps. 
Direct imaging of cells 
In order to identify surface structures as the needle filament, or even needle 
complexes, whole cells could be imaged. Acceptable results were obtained by 
diluting a culture shortly before harvest 1:5 or 1:10 in TE buffer. The cells were 
applied and stained with PTA as described earlier, although the initial settling time 
was raised to 1 minute. 
Electron Microscope 
Negative stain images were taken on a FEI Morgagni transmission electron 
microscope (FEI company, USA) at 80 kV, using an 11 megapixel CCD and the 
iTEM software. 
Secretion profiles: protein precipitation  
To visualize which proteins a strain is able to transport across its membranes to its 
surroundings, the proteins have to be concentrated, which is done here by 
precipitation with trichloroacetic acid (TCA). Adding TCA to the culture supernatant 
lowers the pH to the point at which most proteins cannot be solubilized anymore, and 
form a precipitate. Of course, not all proteins identified in a solution like this are 
transported through the type III secretion system – proteins transported by other 
secretion systems, surface proteins or membrane-permeable proteins will be 
identified as well. All strains tested here are deficient for the flagellar assembly, 
thereby removing a close relative of the type III secretion system. 
A shorter growth period appeared to favour proteins secreted by the needle complex, 
although extended growth tended to increase total signal strength. Lysis of cells and 
thereby unspecific release of type IIII effector proteins appeared not to be an issue 
for the culture conditions described here. The optimal growth period must therefore 
be chosen with the application in mind: for the unambiguous identification of 
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secretion positive or negative strains by immunoblotting, a long growth period might 
be desirable. For secretion profiles, a shorter growth period might help to limit the 
number of nonrelevant proteins in the supernatant. The size of the culture also 
depends on the application, ranging from 20 ml for western blotting and 100 ml for 
secretion profiles. 
A salmonella culture was grown under conditions promoting needle complex 
formation. This was achieved by using culture conditions similar for needle complex 
preparation, with an uninduced preculture over night followed by 5 to 10 hours of 
induced growth, or with direct inoculation and growth over night in liquid LB (0.3 M 
NaCl, 0,012% arabinose, suitable antibiotics), both at 37°C. 
The culture was cleared of cells by centrifugation (5000g, 15 min, 4°C), in tubes 
suitable for the amount of culture volume. Cells of a defined amount of culture (1 
ml) were usually pelleted as an expression control and the supernatant discarded.  
The supernatant of the main culture was passed through a 0.45 µm filter, either with 
a syringe or through a bottle-top filter (Nalgene, US), again depending on the culture 
volume at hand. 
1.5 ml of trichloroacetic acid (TCA, 100% w/v stock solution) were added to 10 ml 
of protein sample and stored at 4°C for at least 60 min. For the following steps, 
centrifuges were cooled to below 0°C. Acetone used for washing the sample was 
stored at -18°C and kept on ice on the bench. 
The precipitate was pelleted by centrifugation in falcon tubes at 8000 rpm, for 40 
min (rotor #3057, Multifuge 3SR, Heraeus, UK), the supernatant was carefully 
discarded and the pellet washed with 1.8 ml cold acetone. The sample could then be 
transferred to 2 ml plastic tubes and was stored at -20°C for 60 minutes or over night. 
Proteins were pelleted in a refrigerated table top centrifuge at maximum speed (13 
krpm, 10 min), the supernatant removed and 1.8 ml of cold acetone (-20°C) added. 
The last stop was repeated, the supernatant taken off and the pellet dried on a heating 
block set to 95°C for a few minutes. The pellet was resuspended in 40 µl H2O and 
60µl 5x Lämmli sample buffer. The buffer usually kept its blue colour, if the 
washing steps were executed properly. If the colour shifts to a greenish or yellow 
hue, the pH could be adjusted to compensate for residual TCA. The sample was 
heated to 98°C for 5 min on a heating block before loading on a polyacrylamid gel.  
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Identification of single protein bands was performed by the in-house protein 
chemistry department, using mass spectroscopy.  
Protein separation: polyacrylamide gels 
SDS Polyacrylamide (PA) gels were prepared according to standard laboratory 
procedures [34]. Commonly used gels include 10 or 12% PA gels, which were 
prepared in advance and stored under humid conditions at 4°C. A 4% loading gel 
was added directly before usage, with 1.5 mm / 10 or 15 lane combs.  
Gradient gels were prepared by combining 5 and 20% PA solutions in a gradient 
mixer, using a econo pump (Bio-Rad, USA). The comb was directly inserted into the 
gradient and the gel polymerized for 60 minutes. Polymerized gels could be stored 
with or without comb at 4°C under humid conditions. For larger gels, the procedure 
was simply upscaled.  
Protein samples were mixed with 5x Lämmli buffer and heated to 99°C for 5 minutes 
before loading. Gels were run using the Bio-Rad Mini-PROTEAN equipment at 20-
40 mA/gel in SDS running buffer. PageRuler™ prestained protein ladder or 
PageRuler™ prestained protein ladder + (Fermentas, USA) were used as a molecular 
weight indicator. 
Coomassie Brilliant Blue staining  
A gel with separated protein samples was removed from the glass chamber, washed 
by placing it in a plastic container with 100 ml of H2O, heating it for 1 minute in a 
microwave oven and letting it slowly shake for 5 minutes. The dH2O was replaced 
and the procedure repeated two more times. The gel was then stained by covering it 
with PageBlue™ Protein Staining Solution (Fermentas, USA) and heating it for 30 
seconds without boiling in the microwave oven. To enhance the staining, the solution 
was left on the gel for 20 minutes while slowly shaking. The gel was then washed 
multiple times with dH2O, preferentially over night to reduce background staining.  
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Immunodetection of proteins (Western Blot)  
A gel with separated protein samples was removed from the glass chamber, washed 
by placing it in a plastic container with 100 ml of H2O and gently shaken for 5 
minutes at room temperature. The H2O was then replaced by protein transfer buffer 
(PTB) [34]., and left shaking for another 10 minutes  
A PVDF membrane (Millipore, Billerica, USA) and a suitable amount of filter paper 
(2x three layers of Whatman® 3MM Chr filter paper) were cut to size. The 
membrane was activated by wetting it with 100% methanol, then washed for 5 
minutes in dH2O, followed by 10 minutes equilibration in 1x PTB. The filter paper 
was wetted using 1x PTB. The transfer of proteins from the gel to the membrane was 
done by using Bio-Rads Trans-Blot SD Semi-Dry Transfer Cell. The components 
were stacked as follows, from bottom to top: three layers of filter paper, the 
membrane, the gel and three layers of filter paper. Trapped air was removed by 
gently rolling a tube over the stack and excess liquid removed from the electrodes. 
Blotting was done at a constant 12 V for 75 minutes.  
After blotting, the membrane was carefully placed in a suitable plastic container, in 
which all incubation steps took place while slowly shaking.  
Additional binding sites were blocked by soaking the membrane in 5% non-fat dried 
milk solved in 0.1% Tween 20 in PBS (PBS-T) for 1h at room temperature or over 
night at 4°C. The membrane was rinsed twice with PBS-T and then placed in a 
dilution of the primary detection antibody in PBS-T. The membrane was incubated 
for one hour at room temperature, or over night at 4°C. Two rinsing steps and three 
washing steps, lasting each 5 minutes in PBS-T, were done before the diluted (PBS-
T) secondary antibody was added for 1 to 2 hours at room temperature. The 
membrane was again rinsed twice and washed three times before the detection 
reagents (Amersham™ ECL Western Blotting Detection Reagents; GE Healthcare, 
USA) were applied. Excessive liquid was carefully removed and the 1 ml of 
detection reagent pipetted and spread over each membrane. After one minute of 
incubation the membrane was placed in transparent film, placed in a x-ray cassette 
and the protein band could be detected by film exposure (Amersham™ Hyperfilm™, 
GE Healthcare, USA) for 10 seconds to 30 minutes. The exposed film was developed 
using a Colenta MP 900 F film developer. 
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Enzyme-linked immunosorbent assay (ELISA) 
Detecting secretion of SptP by ELISA 
The so called secretion ELISA (SecElisa) is an innovative method which allows 
detection of effector molecules directly from culture supernatant. The primary 
advantage is the possibility to test up to 96 samples per multiwell plate, including 
both culture growth and effector detection within 24 hours. It has been successfully 
used so far to test 384 samples per man-day, and is routinely used instead of TCA 
precipitation and western blotting. The SecELISA is established using the 
effector/chaperone pairs SptP/SicP and SipA-Flag/InvB. As only the first pair is 
routinely used, it is the focus of the protocol. 
GST-SicP was expressed in E. coli, the cells lysed and the protein purified by high 
pressure liquid chromatography (HPLC) on a GST-trap column. The final protein 
concentration of SicP for precoating was 60 µg/ml in TBS. 96 well flat bottom 
multiwell plates (300µl, Microtest™ 96-well ELISA plates clear, BD Falcon, US) 
were washed with 100 µl TBS per well and precoated with 100 µl of SicP in solution 
for either 2 hours at room temperature, or at 4°C over night while slowly shaking. 
All liquid was removed and the plates stored at -80°C. Successful ELISAs were 
performed with plates stored for up to a year. 
Bacteria were grown in 2 ml deepwell plates (Riplate® sw 2 ml, Ritter) in 1.8 ml LB 
growth medium (0,3 M NaCl, 0,012% arabinose, antibiotics) for at least 16 hours. 
Culture supernatant was obtained by pelleting cells at 4000g for 15 minutes 
(Multifuge 3 SR, Heraeus, UK). 
Precoated plates were wrapped in paper to avoid condensation and warmed to room 
temperature. During incubation steps, the plate was covered with aluminium foil and 
placed on a shaker, the protocol is best performed at room temperature. A washing 
step consists of adding and removing 200 µl of PBS-T per well. 
Unspecific binding was minimized by blocking with 300 µl 3% bovine albumine 
serum (BSA) in PBS for one hour, after which the blocking solution was removed 
without a washing step. 100 µl of culture supernatant were loaded for one hour to 
capture the effector protein, followed by three washing steps. 100 µl of the first 
antibody dilution (1:3000 monoclonal α-SptP from mouse in PBS-T) were added for 
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one hour, followed by three washing steps. 100 µl of the second antibody dilution 
(1:15000 α-mouse from rabbit, coupled to horse radish peroxidase (HRP)) were 
added for one hour, followed by three washing steps. For the final detection step, 100 
µl of freshly prepares substrate were applied. 3,3´,5,5´-tetramethylbenzidin (TMB) 
was prepared as a 100x stock solution by dissolving 10mg/ml in dimethylsulfoxide 
(DMSO). The working solution is prepared by mixing 100 µl of 100x stock solution, 
2µl of 30% H2O2 and 10 ml 0.1 M citrate buffer (pH 6), and should be at room 
temperature when applied. 
While a blue color was developing, the reaction kinetic could be measured using a 
plate reader (GENios Pro, Tecan, US) at 640 nm. As soon as a distinct blue color was 
displayed, the reaction was stopped using 25 µl of 2 M sulfuric acid (H2SO4) and the 
absorbance was measured at 450 nm. 
Detecting the presence of needle filament by ELISA 
The nonflagellated Salmonella typhimurium strain SB906 [20] carrying the 
transcriptional regulator hilA under the araBAD promoter was complemented by a 
plasmid carrying PrgH with a C-terminal poly-histidine tag (His18). Bacteria were 
grown in 2 ml deepwell plates (Riplate® sw 2 ml, Ritter) in 1.8 ml LB (0,3 M NaCl, 
0,012% arabinose, antibiotics) for at least 16 hours. Cells were harvested by pelleting 
at 4000g for 15 minutes (Multifuge 3 SR, Heraeus, UK), the supernatant could be 
used to perform the SecELISA. The cell pellet was resuspended in 400 µl lysis buffer 
(0.5 M Sucrose in 0.15 M Tris buffer, 0.48 mg/ml lysozyme, 5 mM EDTA) and 
incubated at 14°C for 45 minutes in a thermoshaker. The tubes were then incubated 
at 37°C for 20 minutes at 37°C. This step could be done either in a thermoshaker or 
in a waterbath, depending on the number of samples. 100 µl of LDAO/salt mixture (6 
parts 10% LDAO, 44 parts 5 M NaCl) were added to each sample, followed by 
another 5 minute incubation step at 37°C. 4 µl of MgCl2 are added, followed by a 
similar incubation period. The finished cell lysate was then kept at 4°C for 10-20 
minutes. 
20 µl of the cell lysate were diluted with 80 µl resuspension buffer (PBS, 0.5M 
NaCl, 3% BSA, 0.5% LDAO, pH 8.0). The resulting solution was loaded onto pre-
wetted (resuspension buffer) multiwell plates with nickel-coating (Ni-NTA Hisorb 
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plates, Qiagen, USA), incubated for 1 hour, followed by three washing steps. A 
washing step included adding 200 µl resuspension buffer, slowly shaking the plate 
for 5 minutes and removing the solution. For this protocol, all incubations were 
performed at room temperature on a slowly shaking plate, covered by aluminum foil. 
Antibodies were diluted in resuspension buffer and left on the multiwell plate for 1 
hour. αPrgI (1:2000) was added first and removed by three washing steps after one 
hour incubation time. α-rabbit peroxidase-coupled antibodies (1:10000) were used as 
secondary antibodies, again incubated for one hour and washed off by three washing 
steps. The final detection was performed by adding 100 µl of 3,3′,5,5′ -
Tetramethylbenzidine supersensitive (Sigma, US). As soon as a distinct blue color 
was displayed, the reaction was stopped using 20 µl of 2 M sulfuric acid and the 
absorbance was measured at 450 nm. 
Needle complex MiniPrep 
It is possible to image needle complexes from culture volumes as small as 2-4 ml. 
The lysis protocol described for the structure ELISA can be used to prepare samples 
for EM imaging.  
The resulting cell lysate was cleared by a centrifugation step (7000g, 30 min) in a 
tabletop centrifuge. The needle complexes were pelleted by ultracentrifugation 
(Sorvall RC M150 GX, rotor S100-AT3, 50000 rpm, 30min, 5°C) and resuspended 
in 12-40 µl resuspension buffer 2 (10mM Tris, 0.5M NaCl, , 0.1% LDAO, pH 8.0).  
The sample was then used pure or diluted (1:10) for the negative staining. Usually, 
several needle complexes were found, however significant amounts of additional 
proteins will prevent high quality imaging. 
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RESULTS 
Topology of PrgH and PrgK: site specific labeling 
PrgH C-terminus can be visualized at the interface to InvG 
Initial experiments focused on labeling a his6 tag at the C-terminal end of PrgH. Only 
a small subset of the imaged particles displayed an additional density, located in the 
lower neck region of the base (Figure 1). The interaction between the Ni-NTA 
NanoGold™ and the his6 tag appeared to be specific, but happened either too 
infrequent, or too weak to persist during the final purification and sample preparation 
steps. The low proportion between labeled and unlabeled complexes made a reliable 
2D reconstruction unfeasible (data not shown). 
The length of the tag was increased to 18 histidines to reinforce the binding behavior 
of the gold particles. The functionality of the complex was not impaired by either of 
the tags according to secretion tests [35], but the yield of complexes after a routine 
purification appeared lower compared to a wild-type strain. Gold particles bound 
readily to the his18 tagged needle complexes, resulting in a prominent additional 
density. A number of complexes showed multiple labeled copies of PrgH, resulting 
in a ring-like label around the complex. By using single particle reconstruction [35], 
this ring became easy to identify and positions the C-terminal domain of PrgH in the 
lower neck region of the needle complex (Figure 5D).  
PrgH N-terminus can be visualized at the cytoplasmic tips of the needle complex 
Based on experiences with the C-terminal label, the corresponding N-terminal his tag 
was initially designed with a length of 18 histidines. The resulting strain showed 
secretion activity, but hardly any complexes were obtained after purification. The 
few complexes actually observed had extensive, albeit smeared densities below the 
cytoplasmic face of the structure (data not shown). Given the unusual length of the 
his18 tag, strong interactions between tagged PrgH subunits were assumed. 
Aggregates would then be either formed between PrgH monomers in the cytoplasm 
or the membrane, or between fully formed, tagged complexes during the purification. 
Large protein aggregates would tend to pellet faster, and would therefore be lost 
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during centrifugation steps. To reduce the strength of these interactions and thereby 
reduce aggregation, gradually shorter tags were introduced. 
Strains carrying a his14 and his12 tag on the N-terminus of PrgH were constructed, 
which both exhibited secretion activity. When complexes with a his12 tag were 
purified, unusual aggregation patterns were observed. A rough visual inspection 
showed that hardly any single needle complex was recovered. Most complexes 
interacted via their cytoplasmic side with other complexes, often forming symmetric 
dimers on the EM grid (data not shown). Base structures (without a needle filament) 
appeared to be less prone to aggregate. While a base would readily bind to a needle 
complex, base-base dimers were less commonly observed, possibly related to 
structural changes during needle complex assembly [15]. 
The addition of imidazol, ethylenediaminetetraacetic acid (EDTA) or nickel ions, 
which affect the binding behavior of histidine groups, either during the purification 
process, or to the purified complexes, remained without effect. Similarly, treatments 
with methanol or ethanol tended to destroy complexes before the aggregates could be 
broken up (data not shown). 
A strain carrying an N-terminal his6 tag finally appeared to aggregate only lightly, 
and showed secretion activity. Binding of Ni-NTA-NanoGold™ was robust enough 
to yield a strong signal, although smeared around the innermost tips of the needle 
complex (Figure 5F).  
PrgH M267 is located at the widest point of the inner ring 
Based on the crystal structure of PrgH170–362, secondary structure predictions and the 
mutagenesis screen, a poly-histidine patch was inserted into PrgH after Met267, a 
position known to tolerate a five amino acid long insert (Table 3). Two constructs, 
adding either a his12 or a longer GSG-HHHHHH-GSG sequence abolished secretion 
activity, while a short stretch of his6 was tolerated, resulting in functionally active 
and only lightly aggregating complexes (data not shown). Gold particles could be 
imaged bound to the widest part of the lower ring (Figure 5E), demonstrating the 
relative location of PrgH and offering a valuable reference point for modeling the 
overall topology.  
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Figure 5: Various reconstructions from electron micrographs. Each image was 
created by averaging multiple similar images in order to increase contrast. (A) map 
of the needle complex, selected class averages of (B) wild type needle complex (C) 
gold label at C-terminus of PrgK (D) gold label at C-terminus of PrgH (E) gold label 
at position M267 of PrgH (F) gold label at the N-terminus of PrgH, (G) single needle 
complexes at imaged by cryoEM. Images and reconstructions by Oliver Schraidt. 
 
PrgK C-terminus is located more inwards of the N-terminus of PrgH 
A his18 tag at the C-terminal domain of PrgK (Galán Lab, Yale University, USA) 
prevented successful purification, possibly similar to the problems encountered with 
the N-terminal label of PrgH. The label was therefore exchanged for a his6 tag. The 
resulting strain showed secretion activity and only lightly aggregating complexes. 
The final gold label was located in a comparable position as the N-terminal label of 
PrgH at the cytoplasmic face of the complex, although with a more restricted 
freedom of movement and more confined to the inner opening of the ring (Figure 5C, 
[35]). 
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PrgH can support large N-terminal tags or fusion proteins 
Since tags of varying length at the N-terminus of PrgH were tolerated, an eGFP-
PrgH fusion protein was constructed. The strain was surprisingly able to assemble 
needle complexes and displayed secretion activity (Figure 6A). Purified complexes 
obtained from the strain tended to aggregate, so far only a few complexes were 
visualized (Figure 6C). Confocal fluorescence microscopy was performed on 
bacterial cells in cooperation with Martin Breuss to localize or count needle 
complexes in the bacterial membrane. The resolving power of the convocal 
microscope was insufficient to distinguish individual bacterial features, even after 
applying deconvolution methods. Most of the GFP appeared to be localized at the 
bacterial membrane (Figure 6B). 
 
Figure 6: Summary of strain expressing eGFP-PrgH data. (A) Secretion activity, 
low readout for SB905 due to different growth conditions. (B) eGFP-Prgh expressing 
S. typhimurium, imaged by fluorescence microscopy/deconvolution (Martin Breuss). 
(C) Single needle complexes obtained from an eGFP-PrgH expressing strain 
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Figure 7: Purification of an InvC-PrgH expressing strain. Western blots showing 
(A) expression patterns in various strains (B) Localization of InvC-PrgH on a CsCl 
gradient. Arrow marks potential degradation product.  
 
A similarly constructed InvC-PrgH fusion protein was successfully expressed in 
Salmonella (SB917 – ΔinvC and SB906 – ΔPrgH) and showed secretion activity in 
first trials in the SB917 background. An attempt to purify the strain showed that 
InvC-PrgH was translated, but degradation products were visible on western blots 
(Figure 7A). The full length protein co-localized with needle complex base proteins 
PrgK and InvG on a cesium chloride gradient during purification and therefore has to 
be assembled into the needle complex (Figure 7B). As no needle filament could be 
detected, and secretion activity could only be seen in the SB917 background, it is 
unclear how InvC-PrgH affects the secretion functionality. It seems possible that 
cytosolic InvC-PrgH can rescue the ΔInvC strain, but that the ΔPrgH strain is 
blocked by the addition of only InvC-PrgH. This strain will have to be characterized 
in more detail in the future. It could be a useful tool for the structure determination of 
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the ATPase InvC, as the needle complex might act as a soluble scaffold for the 
assembly of a multimeric InvC complex. 
 
Mutagenesis screen of PrgH 
Establishing ELISAs to assess the assembly and secretion functionality  
The secretion ELISA in its current form, based on the SptP/SicP effector/chaperone 
pair, routinely delivered highly reproducible results. It offered advantages in terms of 
handling and throughput over the immunoblotting based methods [36] used so far. 
The signal obtained from a secretion positive strain was 8 to 15 times higher 
compared to a secretion negative strain (Figure 8). Signal variation between ELISAs 
performed on comparable culture supernatants and pre-coated SicP plates was low.  
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deviation n wells n cultures t-test (vs 906) 
SB905 1,27 0,57 35 8 <0,001 *** 
SB906 0,19 0,11 62 15 1,000  
PrgH-His18 1,01 0,34 46 22 <0,001 *** 
Figure 8: Summary of Secretion ELISA data of multiple cultures. 
 
The protocol lined out in the methods worked well for strains commonly used, but 
has been designed with a limited supply of primary antibodies in mind. Raising the 
concentration of the primary antibody from 1:3000 to 1:2000 or higher increased the 
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*** 
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sensitivity, which might be required for testing strains with hardly any secretion 
activity. Growth conditions and duration of Salmonella culture appeared to influence 
signal intensity drastically. In general, 96-well 3 ml deep well plates offered higher 
throughput for large numbers of samples, but cultures tended to grow to a lower 
optical density and delivered a lower readout compared to cultures grown in larger, 
e.g. 10 ml, culture tubes (data not shown, [37]). Results obtained by the structure 
ELISA followed this pattern closely.  
For routine operation, note should be taken of the stability of chaperone pre-coated 
plates. The oldest plates tested so far had been wrapped in aluminum foil and stored 
at -80°C for over a year without apparent degradation. 
Details on the structure ELISA are described in the diploma thesis of Julia Radics 
[37]. Conceptionally, assembling the needle complex is a strictly stepwise process, 
with each successive step relying on the completion of the prior step. By screening 
assembled complexes for the presence of stage-specific proteins, the consequences of 
mutations on the assembly process can be inferred. Here, the presence of the needle 
filament protein PrgI was used as a marker for a fully assembled needle complex, 
which would structurally be able to transport proteins into the culture supernatant.  
Initial experiments used a C-terminal his6 tag on PrgH to capture the needle complex 
and were only of limited success. Similar to the improved binding of an extended C-
terminal his18 tag to Ni-NTA gold particles seen in the topology studies, a strain 
carrying a C-terminal his18 tag also gave higher readings in the structural ELISA. 
Further improvements of the protocol as well as using a more sensitive substrate for 
the detection reaction finally allowed successful detection of the finished assembly. 
Mutagenesis screen 
By using the GPS®-LS Linker Scanning System (NEB, US) a primary library of 
plasmids with random 15 base pair (bp) long insertions within the insert (Promoter 
and PrgH-his18) of the plasmid used was produced. 5 bp were duplicated from the 
site of insertion, the remaining 10 bp encoded, depending on the reading frame, a 
cysteine, lysine or stop codon, surrounded by other amino acids.  
From roughly 1200 sequenced plasmids a library of initially 87 unique plasmid was 
selected, which was reduced to 75 plasmids during the course of the experiment due 
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to sequencing errors, phage contaminations or irreproducible results for certain 
strains. Each plasmid contained a mutation resulting in a 5 amino acid insert in the 
coding sequence of PrgH. On average, these mutations were spaced 16.2 base pairs 
apart (±16.3 STD).  
The primary library of 1200 plasmids also contained variants with mutations in the 
500 bp upstream promoter sequence, one or more stop codons within PrgH or more 
than one mutation within the insert. No systematic analysis was done on these 
additional strains, but PrgH variants with stop codons close to the C-terminus were 
observed to affect needle complex stability (pers. comm. Julia Radics) and allowed 
to pinpoint interactions between PrgH and InvG [35]. 
The library was screened both for the presence of needle filament as a marker for 
completion of the assembly process, and secretion of SptP by ELISAs. Each test was 
performed at least three times from independent cultures, plus additional experiments 
if conflicting results were obtained. A strain was considered to deliver a positive 
signal if the readout of the ELISA exceeded a threshold calculated at the average of 
the negative control plus 3 times the corresponding standard deviation.  
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Figure 9: Conversion graph to estimate the optical density of a bacterial culture. 
Tables 1-4 give the OD value as obtained from a multiplate reader, and have to be 
converted to conform to values obtained from commonly used 10mm cuvettes. 
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Of seventy-five strains tested, forty-four were found to completely assemble needle 
complexes and thirty-seven were actively secreting SptP (Table 1-4). Looking at the 
cytoplasmic, N-terminal domain (1-140 AA) and the periplasmic, C-terminal domain 
(140-392 AA, including a predicted transmembrane helix) separately allows a more 
detailed analysis. The density of mutations was slightly higher for the shorter N-
terminal domain (30 strains) compared to the C-terminal domain (45 strains).  
 
 
Figure 10: Diagram showing structure and secretion ELISA results for each of 
the 75 mutations. The dashed line represents the lower level (0.27) above which a 
strain was considered to form needle filament. For the secretion ELISA the 
corresponding level was calculated at 0.30, but not drawn here (table 4). 
 
Mutations on the C-terminal domain of PrgH 
Of the forty-five strains in the C-terminal domain, twenty were found to assemble 
needle complexes compared to twenty-five which failed to do so (Table 1-2). 
Twenty-one strains were secretion competent, and twenty-four failed to secrete SptP. 
Three strains were found in which a positive signal of one ELISA was not mirrored 
by the other ELISA. 
Two strains, one containing the insert within the his18-tag, one eleven amino acids 
upstream of the tag, were found to secrete SptP, but no signal could be detected in 
the structural ELISA. As the length of the his-tag was found to be important early 
during the development of the structural ELISA, these strains most likely produced 
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needle complexes unable to bind sufficiently strong to the ELISA plates to allow 
detection.  
One strain (insert Leu331) appeared at first glance to be positive for needle complex 
assembly, but the readout for the SecELISA remained slightly below the threshold. 
The strain showed some variation in the secretion activity, as indicated by the 
corresponding standard deviation. Data obtained from secretion profiles and western 
blot analysis suggests that the strain is secretion competent, although at a very low 
level. Given that both StrucELISA and SecELISA results are rather low, the strain 
most likely only produces a minute amount of needle complexes, but is in principle 
secretion competent. 
Based on the recent, more precise [19, 35] docking of PrgH and PrgK into the overall 
electron density map, the loop containing the mutation protrudes into the central core 
of the basal body. With the limited resolution of the currently available model any 
explanation is bound to be vague, but it appears likely that additional amino acids 
within the structure could easily cause steric disturbances, apart from changes in 
local chemical properties of the side-chains. It might be interesting to see if Leu331 
of PrgH interacts solely with PrgH, or if the protein is also involved in stabilizing the 
inner rod or cup region of the complex.  
Visualizing the mutations of the on the recently published [18] crystal structure of 
the truncated C-terminal domain (AA 170-362) showed that those insertions, that 
still allow needle complex assembly, map to connecting loops. Mutations resulting in 
a loss of function map onto either alpha-helices or beta-sheets. 
Mutations on the N-terminal domain of PrgH affect secretion of SptP 
Of the thirty mutant strains covering the N-terminal domain, twenty-four assembled 
needle complexes while six were unable to do so (Table 2-3). Secretion activity was 
only found for sixteen of the strains, while for fourteen strains no secretion was 
detectable. The mutations in the eight strains, which appear to be able to assemble 
non-functional needle complexes, map to four different areas. One large stretch was 
located between Leu24 to Val39, a short stretch between Phe61 to Leu64 and two 
hotspots around Ile9 and His85. Here, at His85, two different inserts showed a 
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slightly different behavior: CLNIH abolished secretion, while VFKHH still allows 
very weak secretion to take place. 
Similar to the C-terminal domain, mutations not affecting structure assembly or 
secretion activity mapped to areas between predicted secondary structure elements 
(data not shown).  
Mutations differ in their effect on secretion of SptP, SipB and SipC  
To verify the results obtained by the secretion ELISA for SptP, and to test the 
influence of the mutations on other secreted proteins, secretion profiles were 
obtained. The complexity of the sample prevented any detailed analysis based on 
coomassie protein gels and protein fingerprinting by mass spectroscopy (Figure 11), 
therefore western blotting was used to test for the presence of secreted proteins in the 
culture supernatant. All strains with mutations located between AA14 to 363 and 
producing fully assembled complexes according to the StrucELISA, were grown 
under conditions promoting formation of needle complexes. Proteins from the culture 
supernatants were precipitated. Western analysis was done using monoclonal 
antibodies against SptP, SipB and SipC. The readout obtained for SptP mostly 
confirmed the readout of the SecELISA, with three exceptions that will have to be 
verified. The strains in question are AA14AA85 and AA117, all of which show no 
secretion of SptP according to immunodetection. At position AA85, two different 
inserts were available. One strain contained a CLNIH insertion, the other VFKHH. 
Originally, both mutations were found to be secretion negative, in later retests the 
strain containing a VFKHH insert secreted SptP, although very slowly. Similarly, the 
strain carrying a mutation at position AA14 was originally classified secretion 
negative by SecELISA data, but later confirmed to be secretion active (Figure 12). 
As predicted by the data collected through the SecELISA, SptP secretion was 
abolished by several mutations between AA24 to 39, AA61-64 and AA 85-117. 
Surprisingly, other secreted proteins were not affected to the same degree by the 
mutations.  
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SipB could be secreted by all but two strains, although some slight variations in the 
amount of SipB in the supernatant were detected, judged from the relative intensity 
of the corresponding bands. The two exceptions were those containing inserts after 
Phe61 and Leu64. The second strain later showed no assembly of needle filament, 
thereby explaining the inability to secret any of the three proteins. Given this 
information, the reason for the high readout of the StrucELISA is unclear. 
SipC was similarly secreted by all strains except for those with inserts at Phe61 and 
Leu64. In contrast to SipB, the amount of secreted SipC varied greatly between 
different strains, and was hardly detectable in two strains. 
The area between Leu 24 and Val 39, as well as the hotspot around His 85 already 
identified by the ELISA based screen was thereby verified to play a role in secretion. 
Overall, the mutations as generated here affect the three secreted proteins differently. 
SipB secretion appears to be fairly robust, whereas SptP appears highly sensitive to 
mutations, with SipC showing intermediate sensitivity.  
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DISCUSSION 
Fitting PrgH & PrgK into an experimentally verified model of the needle 
complex 
In recent years, a number of 3D structures related to type three secretion systems 
have become available. Structural data at atomic resolution is available for truncated 
subunits (as PrgI [38]) and a number of domains derived from PrgH [18], the InvG 
homolog EscC [18] and the PrgK homolog EscJ [39]. In addition, the structures of 
needle complexes from Salmonella typhimurium [15] and Shigella flexneri [13] were 
published at lower resolutions. Since the needle complex itself is considered to be 
highly conserved across a number of organisms [40], the attempt to integrate these 
proteins into a single model despite the varied origin is well accepted. Due to 
inconclusive [13, 15, 18] data on the copy number of various subunits respectively 
the overall symmetry of the needle complex, restraints for the model building process 
have been missing, resulting in a number of conflicting suggestions for the placement 
of subunits.  
Needle complexes obtained from a ∆InvG mutant lack the outer ri ng structure, 
thereby allowing placement of PrgH and PrgK in the remaining, prominent inner ring 
[35]. By studying the surface accessibility of lysines and through structural restraints 
created from cross-linking experiments, the topology map for Salmonella has already 
been refined with relative positional data [41]. This allowed locating the C-terminus 
of PrgH close to the N-terminus of InvG, and the C-terminus of PrgK close to the N-
terminus of PrgH. Additionally, and in contrast to PrgK, the surface of PrgH 
appeared to be accessible for solvents. With the data presented in Figure 5, the 
orientation of PrgH relative to InvG and PrgK as indicated by cross-linking 
experiments can be confirmed. 
With the orientation and maximum extension of PrgH towards the neck region given 
by the C-terminal gold label, and a specific label for the loop region around M267, 
the crystal structure of the C-terminal domain of PrgH can now be fitted into the 
existing electron density map with high confidence. Using gold labels at the C-
terminal end of PrgK to determine the relative orientation and additional data gained 
from top-views of the inner rings, PrgK could be docked in a ring-like structure 
-58- 
within the encompassing PrgH ring [35]. One of the so far less favored models [18] 
can therefore be verified and expanded upon, as first published in [35] shown in 
Figure 13. 
 
 
Figure 13: Topology model of the needle complex. PrgH forms the large outer ring 
and encloses the smaller ring created by PrgK. InvG interacts with its N-terminal 
domain with the C-terminus of PrgH. Originally published in [35].  
 
Mutagenesis of PrgH 
Ratios of ELISA-readouts allow identifying distinct domains in PrgH 
With the topology of PrgH firmly established, the effects of short inserts on its 
various domains could be visualized. For the initial analysis, strains were simply 
evaluated as showing positive or negative results depending on a defined threshold 
level, following a nomenclature of (+/+), (-/-) and (+/-) with the first symbol 
corresponding to the StrucELISA result, and the second to the SecELISA result. (+/-) 
strains would be fully assembled complexes, with mutations preventing successful 
secretion of SptP. Tables 1-4 indicate this nomenclature by green (+) and red (-) 
background of the respective ELISA readout.  
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Here, the ratio of the StrucELISA to each SecELISA result per strain was calculated 
and plotted over the protein sequence for all strains with a StrucELISA signal above 
the threshold level. Incidentally, inclusion of StrucELISA negative strains would not 
change the result, as the ratio for (-/-) strains varies within a very narrow corridor, as 
negative results from either ELISA display little variation. 
 
0
5
10
15
0 50 100 150 200 250 300 350 400
amino acid sequence
R
at
io
 S
tr
uc
EL
IS
A
 to
 S
ec
EL
IS
A
amino acids 6-14, 117-331
amino acids 24-85
amino acids 363-403
 
Figure 14: Diagram plotting the ratio of structure ELISA to secretion ELISA. 
Only strains positive for needle complex assembly were used for the calculation. 
Outliers were used to mark the beginning and the end of four sequence ranges. 
 
 
 
 
Sequence range 6-14,117-331 24-85 363-403 
Average ratio 1,19 3,71* 0,72*** 
t-Test 1,000 0,024 0,001 
 
Figure 15: Diagram showing the average ratio for each of the four sequence 
ranges. The first and third sequence ranges were consolidated, considered as 
baseline and a t-test performed against the second and forth sequence range. 
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While the absolute value of the ratio is necessarily arbitrary, and cannot be used to 
compare data collected from independently performed experiments, it can be used to 
compare strains within this closed data set. A plot showing the calculated ratios over 
the sequence of PrgH is given in Figure 14. The advantage of this visualization lies 
in the idea that it removes variations that affect both the SecELISA and the 
StrucELISA, such as a lower culture density compared to other strains, or complexes 
that are inefficiently assembled but show normal secretion activity once completed. 
This type of analysis is commonly used for other assays. 
A ratio lower than average can be caused by failure to detect needle complexes, e.g. 
through mutations close to the his18 tag, shorter needle filaments or increased 
secretion of SptP. A ratio higher than average can be caused by needle complexes 
binding with higher affinity to the Ni-coated plates, a longer needle filament, 
unspecific binding of PrgI due to conformational changes or a reduced amount of 
SptP in the culture supernatant. 
Analyzing individual ratios would be unwarrantable, due to the inherent noise. By 
looking at averages over fairly large areas of the protein, three very distinct domains 
could nevertheless be identified, with on average significantly higher and lower 
ratios Figure 15. The start and end of each domain was determined by the first outlier 
above or below average ratios, and corresponds very well with domains identified in 
the literature. 
The very C-terminal domain beyond residue 362 has been identified as a linker 
domain before, interacting with N-terminus of InvG in order to connect the inner and 
outer rings of the base structure [35]. The highly significant drop in the readout for 
the StrucELISA observed in this domain is therefore most likely related to needle 
complexes being destabilized [35] by mutants, or changes in the accessibility of the 
his tag.  
The N-terminal domain appears prone to mutations decreasing or abolishing 
secretion activity, and thereby shifting the ratios on average higher.  
Mutations in the N-terminal domain of PrgH affect secretion 
Core proteins of the needle complex (InvG, PrgH, PrgK, PrgI, PrgJ) or their 
respective homologs are regularly recovered from purified needle complexes [31] 
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and can in principle be considered conserved across multiple organisms. Looked 
upon in detail, the connection between PrgH and its homologs (YscD, EscD, MxiG, 
CdsD) appears less clear [6]. While the general organization of the protein with an 
N-terminal Forkhead-associated-domain (FHA) [42, 43], a transmembrane helix, a 
C-terminal ring-forming motif [18] and a putative phospholipid-binding domain 
(BON) [42] appears to be similar, overall sequence conservation is fairly low. 
 
Figure 16: Alignment of the n-terminal domains of various PrgH homologs.  
Green boxes mark the predicted FHA domain [42], red boxes mark regions likely to 
produce secretion-negative needle complexes identified in the mutagenesis screen.  
Sequences were aligned using the ClustalW2 [44] web service provided by EMBL-
EBI and formatted using default CHROMA [45] settings: Consensus abbreviations 
(amino acids): a, aromatic (FHWY, blue lettering on a dark yellow background); b, 
big (EFHIKLMQRWY, blue on light yellow); h, hydrophobic (ACFGHILMTVWY, 
black on dark yellow); l, aliphatic (ILV, grey on dark yellow); p, polar 
(CDEHKNQRST, blue on white); s, small (ACDGNPSTV, dark green on white); t, 
tiny (AGS, light green on white); -, negatively-charged (DE, red on white); and, +, 
positively-charged (KR, blue on white), c, charged (DEKRH, pink on white. 
Organism and gene name abbreviations used: Sf: Shigella flexneri MxiG (P0A221), 
Yp: Yersinia enterocolitica YscD (Q93KT0), Ec: Escherichia coli EscD (O86193), 
St: Salmonella typhimurium PrgH (P41783), Cp: Chlamydia pneumoniae CdsD 
(Q9Z7J3) 
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FHA domains were originally mapped to 50-70 amino acids long protein sequences, 
the domain has since been revised to contain 120-140 amino acids, which would 
easily include the whole N-terminal domain of PrgH. FHA proteins canonically bind 
to phosphorylated serine, threonine or tyrosine, with five essential conserved amino 
acids described, localized in loops between the beta-sheets of the domain [46]. So 
far, no data on phosphorylated proteins in the type three secretion system of 
Salmonella is available. 
In the mutagenesis screen described here, short insertions in the N-terminal domain, 
specifically in the predicted FHA region of PrgH affected the transport of both 
proteins considered [2] middle (translocators SipB, SipC) and late (SptP) secretion 
substrates, although to a different extent. Multiple strains unable to secrete SptP still 
transported SipB into the culture supernatant, and only showed slightly reduced 
secretion of SipC (Figure 12). 
All of the mutations resulting in (+/-) strains mapped either directly upstream of the 
predicted FHA domain into a highly conserved region, or directly into the domain 
itself (Figure 16). Since five amino acid long inserts were used for the mutagenesis 
presented here, it is difficult to assess if and to what extent conserved residues of the 
FHA domain were involved in the observed phenotypes. Additional studies, focusing 
on creating point mutations in the critical areas identified here, and an atomic 
structure of the relevant domain will be necessary to uncover the exact interaction 
site.  
Possible roles of the N-terminal domain of PrgH 
Variations in the secretion of multiple proteins as observed in the strains obtained 
from the mutagenesis screen might be explained by direct interactions between the 
chaperones/effectors and PrgH. The domain was located in the cytoplasm and 
showed enough freedom of movement to suggest a specific role in supplying bound 
effectors to a hypothetical ATPase complex nearby. The specific impact of a 
mutation would then depend on the affinity and binding surface for each protein, 
with stronger interactions being harder to disrupt than weaker interactions. Variations 
in the affinity of effectors to the secretion machinery have been observed and 
modeled [26] to be sufficient to cause hierarchical secretion. Since the translocators 
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SipB and SipC are secreted earlier than the late effector SptP, this working model 
would explain the data very well. Unfortunately, preliminary experiments failed to 
show interaction between a number of effectors and PrgH (data not shown).  
An extensive review of the literature did not return any known interactions between 
homologs of PrgH and effectors or chaperones, although another potential interaction 
partner was discovered, as discussed below.  
An additional model closely fitting the data could be constructed based on the idea of 
a generally slowed secretion process, without specific effect on any secretion 
substrate. If proteins were secreted in a hierarchical manner, a secretion apparatus 
hampered by a severe mutation would not be able to progress towards the later 
repertoire of effector proteins and would show diminished levels of these proteins in 
the culture supernatant. In Salmonella typhimurium, the effector pool of a cell can be 
moved through the type three secretion system within minutes of contact with a host 
cell [26]. Secretion tests were performed over several hours, offering some protection 
against this problem. At this point, this model cannot be ruled out, until the effect of 
the mutation against additional secretion substrates can be studied.  
C-ring proteins interact with PrgH homologs 
The type three secretion system consists of the needle complex and a cytoplasmic 
bulb, or c-ring [6]. This additional structure contains the ATPase InvC [47] and 
regulatory proteins such as SpaO, OrgA and OrgB, and is conserved in multiple 
organisms. Strains lacking InvC or other proteins of the c-ring fail to assemble 
needle filaments and are unable to secrete early substrates as PrgI [20]. Since most of 
the (+/-) mutants appeared to be fully assembled (with the exception of mutation 
AA61), it appeared unlikely that the interaction between the needle complex and the 
c-ring was completely disrupted.  
Figure 17 summarized the data obtained from aggregating multiple yeast2hybrid 
screens performed in different organisms. In Shigella flexneri, interactions between 
the core c-ring proteins have been mapped exhaustingly. The complete interaction 
map includes interactions between MxiG (PrgH) and MxiJ (PrgK) to Spa33 (SpaO). 
The latter one interacts with the ATPase Spa47 (InvC), which is bound by the 
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regulatory proteins MxiK and MxiN (OrgA, OrgB). Interactions between Spa33 and 
middle or late effector proteins were also shown [32, 48].  
 
 
Figure 17: Illustration of interactions between basal and cytoplasmic proteins of 
the type 3 secretion system according to current literature [32, 48-52]. Published 
data from yeast2hybrid screens showing interactions between several conserved 
proteins belonging to the type three secretion system in five different organisms.  
 
Studies in other organisms are less comprehensive, but all interactions shown so far 
follow the pattern laid out in Shigella flexneri, and suggest a conserved mechanism. 
In Yersinia pestis interactions of the ATPase YscN with SpaO homolog YscQ, and of 
OrgA/B homologs YscL/N with YscQ were shown [50]. In Chlamydophila 
pneumoniae interactions between the potential distant PrgH homolog CdsD, CdsQ 
(SpaO) and CdsL (OrgB) [51] were shown, and additional interactions between those 
three proteins and the ATPase, specifically the first 105 amino acids of CdsN [52]. 
Overall, the picture here is less clear, probably related to an additional 400 AA long 
domain in CdsD, showing a second FHA domain. In Escherichia coli and Salmonella 
typhimurium, no interaction between the c-ring proteins and the needle complex were 
shown so far.  
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Current models cannot explain the phenotype of FHA domain mutants 
The earlier described model on direct interactions between chaperones/effectors with 
PrgH would readily explain the observed phenotypes, but is most likely incorrect. 
Given the current understanding of the cytoplasmic, peripheral type three secretion 
system protein network, no conclusive mechanistic explanation for the interplay 
between the FHA domain of PrgH and c-ring proteins, or even the C-terminal 
domain of PrgK can be given. In principle, the three hotspots identified could 
correspond to binding sites for several separate proteins. 
Besides the C-terminus of PrgK, SpaO is the likeliest candidate for direct interactions 
with PrgH. Mutations preventing binding of SpaO to PrgH should result in a 
phenotype similar to a knockout of SpaO, with no secretion of either early, middle or 
late proteins. Despite high readouts from the StrucELISA, strains with inserts at 
position AA61 and AA65 show no secretion activity for middle to late substrates, 
and no needle filament could be detected on purified complexes by electron 
microscopy from strain AA61 (AA65 was not yet analyzed). This might suggest 
either a critical binding site in this position, or disruption of the protein fold due to 
the mutation. 
The other mutations between AA24-39 and around AA85 appeared to specifically 
select against secretion of late (effector) substrates, but still allowed secretion of 
translocators. So far, two proteins were linked to phenotypes relevant to translocator 
secretion.  
Mutants of InvE [53] in Salmonella and YscU in Yersinia [54, 55] will secrete 
effector proteins, but not translocators. YscU is an autocatalytic protein, whose 
cleavage is required to switch the needle complex from secreting early stage proteins 
to translocators. An inactive YscUN263A strain therefore ignores the secretion switch 
towards translocators and proceeds directly to secrete late substrates. InvE has been 
shown to interact with the chaperone-effector complex SicA/SipB and SicA/SipC, 
and appears to bind to a membrane-associated protein [53].  
Given the data presented so far, it might be possible to present a hypothetical model 
in which two partly independent mechanisms exist for the recognition of middle and 
late secretion substrates. The translocator/chaperone complexes (SipB and 
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SipC/SicA) would here be dependent on the activity of the YscU homolog SpaS and 
binding of InvE to the needle complex or c-ring. This interaction could either occur 
at independent or only partially overlapping sites with high affinity compared to the 
recognition of late chaperone/effector, or to separate binding sites formed by as of 
yet not identified regulatory proteins. InvE only interacts with the chaperone-effector 
complex, and not with either alone. Hypothetically, this could lead to self-regulation 
once the translocator pool is depleted, as InvE would run out of binding partners and 
dissociate from the needle complex. 
In this model, the mutations in the FHA domain of PrgH would disrupt the 
interaction sites of protein/chaperone complexes of late substrates as SptP/SicP on 
the ATPase or the c-ring in general, possibly by not allowing interactions with 
regulatory proteins or through a general destabilization of the c-ring. The successful 
secretion of translocator proteins on the other hand would be caused by the use of 
separate recognition sites or through stabilization of the interaction between the c-
ring and the needle complex by additional membrane associated proteins.  
Outlook 
To further understand the complex regulation of the type three secretion process, it 
will be necessary to approach a number of research questions opened up by the work 
presented here.  
So far, no interaction of the N-terminal domain of PrgH with a cytoplasmic protein 
was shown. The most promising approach appears to be identifying interactions in 
vitro, most likely based on the candidates discussed here. Once an interaction partner 
is identified, the interaction will have to be characterized in detail, to answer the 
questions in regard to the identified hotspots representing independent binding sites. 
While the usage of short, five amino acid long insert proved to be a very useful 
compromise to keep the number of strains low while maintaining good coverage, the 
effects of the inserts on the protein fold shouldn’t be neglected. It would be 
preferable to understand the role of individual amino acid residues by screening a 
library of point mutations, especially since the areas of interest have already been 
identified and the necessary tools for high throughput screening are in place.  
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As the topology of PrgH in the needle complex is now firmly established, its 
potential capacity to link the basal body to the complex cytoplasmic machinery is a 
surprising discovery. So far, structural studies have focused on the prominent needle 
complex, with hardly any available structural data on proteins forming the c-ring. 
Ultimately, in order to understand the complex machinery evolved to aid the survival 
of bacteria in a hostile environment, these gaps will have to be filled. 
-68- 
PLASMIDS AND STRAINS 
 
Strain Plasmids Construct backbone AB cloning sites 
SB906 pWS006 
PrgH, 500bp upstream, 18xHis C-
terminal, C27A, BsaHI site 
upstream TATA 
pwsk29 AMP HindIII, XmaI 
SB906 pWS007 PrgH, 500bp upstream, 12xHis N-terminal pwsk29 AMP 
PstI, 
NotI 
SB906 PWS008 PrgH, 500bp upstream, 14xHis N-terminal pwsk29 AMP 
PstI, 
NotI 
SB906 pWS009 PrgH, 500bp upstream, 18xHis N-terminal pwsk29 AMP 
PstI, 
NotI 
SB906 pWS014 PrgH, 500bp upstream, 6xHIS N-terminal pwsk29 AMP 
PstI, 
NotI 
SB906 pWS016 
PrgH, 500bp upstream. NdeI & 
BamHI site for cloning of 
upstream elements 
WS200s AMP PstI, NotI 
SB906 pWS017 eGFP + linker cloned between NdeI/BamHI of WS016 pWS016 AMP 
PstI, 
NotI 
SB906 pWS018 PrgH, 500bp upstream, 6xHIS-PrgH after M267 pwsk29 AMP 
PstI, 
NotI 
SB906 pWS019 PrgH, 500bp upstream, GSG-6xHIS-GSG-PrgH after M267 pwsk29 AMP 
PstI, 
NotI 
SB906 pWS020 PrgH, 500bp upstream, 12xHIS-PrgH after M267 pwsk29 AMP 
PstI, 
NotI 
SB906 pWS021 InvC-PrgH-fusion, 500bp upstream, cloned into pWS016 pwsk29 AMP 
PstI, 
NotI 
SB917 pWS021 InvC-PrgH-fusion, 500bp upstream, cloned into pWS016 pwsk29 AMP 
PstI, 
NotI 
SB905 pPrgI5 PrgI, ~900bp upstream pwsk29 AMP PstI, NotI 
Table 5: Overview of all strains and plasmids used in this study. SB905: non-
flagellated wild-type, SB906: non-flagellated ΔprgH, SB917: non-flagellated ΔinvC 
[20]. AMP : Ampicillin. All strains carried an additional plasmid containing the 
transcriptional regulator hilA under the araBAD promoter with an chloramphenicol 
(CMP) resistance marker. 
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The type III secretion system (T3SS) is essential for the infectivity of many
pathogenic Gram-negative bacteria. The T3SS contains proteins that form a
channel in the inner and outer bacterial membranes, as well as an
extracellular needle that is used for transporting and injecting effector
proteins into a host cell. The homology between the T3SS and the bacterial
flagellar system has been firmly established, based upon both sequence
similarities between respective proteins in the two systems and the
structural homology of higher-order assemblies. It has previously been
shown that the Shigella flexneri needle has a helical symmetry of
∼5.6 subunits/turn, which is quite similar to that of the most intensively
studied flagellar filament (from Salmonella typhimurium), which has
∼5.5 subunits/turn. We now show that the Sa. typhimurium needle,
expected by homology arguments to be more similar to the Sa. typhimurium
flagellar filament than is the needle from Shigella, actually has ∼6.3 sub-
units/turn. It is not currently understood how host cell contact, made at the
tip of the needle, is communicated to the secretory system at the base. In
contrast to the Sa. typhimurium flagellar filament, which shows a nearly
crystalline order, the Sa. typhimurium needle has a highly variable
symmetry, which could be used to transmit information about host cell
contact.
© 2010 Elsevier Ltd. All rights reserved.
Edited by R. Craig
Keywords: cryo-electron microscopy; helical reconstruction; protein poly-
mers; bacterial pathogenesis; structural polymorphism
Introduction
Many pathogenic Gram-negative bacteria contain
type III secretion systems (T3SSs) that are essential
for infectivity.1 These T3SSs serve as both a secretion
system and an injection system for bacterial effector
proteins that need to be passed through the inner
and outer bacterial membranes and into a host cell.
The strong morphological and sequence similarities
between the T3SS and the bacterial flagellar system
gave rise to the suggestion that these systems are
homologs, having common origins.2,3 Consistent
with this, it was shown4 that the needle of the
Shigella flexneri T3SS has approximately the same
helical symmetry (5.6 subunits/turn of a 24-Å-pitch
helix) as the best-characterized flagellar filament5—
that from Salmonella typhimurium (∼5.5 subunits/
turn of a 26-Å-pitch helix). Since contact between the
bacterium and the host cell has been shown to
switch the T3SS into a secretory state, attempts have
been made to find changes in the helical structure of
the Sh. flexneri needle with mutations in the needle
protein MxiH, which lock the T3SS into a constitu-
tive “on” state.6 Given the homology between the
T3SS and the flagellar system, it was thought that a
switching of the state of the needle might occur
similarly to the switching of the flagellar filament
from a left-handed state to a right-handed state of
protofilaments.7 These studies6 failed to find any
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changes in average helical parameters, leading to the
suggestion that such changes in helical symmetry
might be too small to be detected by the analysis
methods used, or that signal transduction in this
system occurs through some novel mechanism that
has not yet been characterized.
Results
Sa. typhimurium needles have been imaged by
both negative staining (Fig. 1d) and cryo-electron
microscopy (cryo-EM) (Fig. 1a and g). Fields of
needles imaged by cryo-EM (Fig. 1a) were used to
generate an averaged power spectrum (Fig. 1b) that
is quite similar to a fiber diffraction pattern, as it
shows no sampling due to an ordered arrangement
of filaments. This power spectrum shows only three
layer lines: one at ∼1/(26 Å) arising from a 1-start
helix, a more diffuse one at ∼1/(38 Å), and a very
diffuse one at ∼1/(85 Å). The broadening of these
other layer lines is a characteristic feature of
variability in the twist of a helical structure,8
where helical symmetry is not exactly conserved
between every adjacent subunit. As a result, devia-
tions in twist accumulate along a filament, and long-
range order does not exist. Indexing these two more
diffuse layer lines was problematic, as multiple
solutions consistent with the diameter of these
particles are possible. The layer lines at 1/(38 Å)
and 1/(85 Å) could have any Bessel order less than 8.
The power spectrum at this resolution simply does
not uniquely specify the helical symmetry due to the
fact that, for many structures at limited resolution,
there are intrinsic ambiguities in determining helical
symmetry.9 Similarly, multiple solutions can be
obtained with the iterative helical real space
reconstruction (IHRSR) method.10 For example, a
schemewith 1/(38 Å) being n=−3 andwith 1/(85 Å)
being n=4 (3.7 units/turn), and a scheme with 1/
(38 Å) being n=7 and with 1/(85 Å) being n=−6
(6.3 units/turn) both led to stable solutions, with
reconstructions generating power spectra indistin-
guishable from the power spectra generated from
Fig. 1. (a) Cryo-EM image of bundles of needles. (b) Averaged power spectrum generated from 14 nonoverlapping
boxes (512×512 pixels, 5.9 Å/pixel) taken from bundles such as in (a). (c) STEM mass histogram, with a Gaussian curve
fitted. (d) Negatively stained needles. (e) Averaged negative-stain power spectrum from 259 nonoverlapping boxes, each
480 pixel long (1.33 Å/pixel). (f) Overall IHRSR three-dimensional negative-stain reconstruction derived from 5420
segments (120 pixels long, 5.32 Å/pixel), filtered to 24 Å resolution. This reconstruction converged to a helical symmetry of
57° rotation and an axial rise of 4.2 Å, corresponding to 6.3 subunits/turn of a 26.5-Å-pitch helix. (g) Cryo-EM of isolated
filaments. (h) Averaged cryo-EM power spectrum from 850 nonoverlapping boxes, each 480 pixels long (1.33 Å/pixel). (i)
Overall IHRSR cryo-EM three-dimensional reconstruction derived from 22,834 segments (120 pixels long, 2.66 Å/pixel),
filtered to 24 Å resolution. This converged to the same symmetry as the negative-stain reconstruction (57°/4.2 Å).
1393Sa. typhimurium Type III Secretion System Needle
the images. We therefore used scanning transmis-
sion electron microscopy (STEM) to obtain an
accurate estimate of mass per unit length in these
needles.11 STEM measurements indicated that the
average mass per length was ∼2.0 kDa/Å (Fig. 1c).
Since the component protein of the Sa. typhimurium
needle, PrgI, contains 80 residues and is 8.4 kDa, this
would suggest that the axial rise per subunit is, on
average, ∼4.2 Å, and that there are, on average,
∼6.2 subunits/turn of the 26-Å-pitch 1-start helix.
This knowledge of mass per length was then used
to generate overall reconstructions of the needles
from both negative staining (Fig. 1f) and cryo-EM
(Fig. 1i). The failure of the IHRSR method to
converge to the same solution from different starting
symmetries, as well as the broad layer lines seen in
the averaged power spectrum from bundles (Fig.
1b), strongly suggested that these samples were
heterogeneous with respect to helical parameters.
Power spectra computed from subsets of the
filaments after sorting (Supplementary Movie 1)
show the very large variability in twist, with a range
that extends beyond 6.2–6.5 subunits/turn. Supple-
mentary Movie 1 displays a fixed n=7 layer line at
∼1/(38 Å), with a very variable n=−6 layer line.
The best reconstruction (Fig. 2a) was obtained
from the central bin (6.3 subunits/turn) of the cryo-
EM filaments, using 9366 segments from a total of
22,834 segments. The most conservative estimate14
of the resolution of this reconstruction is 19.5 Å,
using a Fourier shell correlation of 0.5, and two
completely independent reconstructions were gen-
erated from different starting symmetries and using
completely different images. This actually provides
an estimate of the resolution for a reconstruction
containing half of the total images and must
therefore be an underestimate of the resolution of
the full data set. Filtering an atomic model of the
two-helix bundle within the PrgI subunit12 (residues
18–60; Fig. 2a) to 18 Å resolution provides a good
Fig. 2. (a) Reconstruction of the frozen hydrated filaments filtered to 18 Å resolution, using 9366 segments from a total
of 22,834 segments. Sorting was based on variable twist and axial rise while keeping the n=+7 layer line fixed at 1/(38 Å).
This class from the center of the distribution yielded a symmetry of 57°/4.2 Å. Residues 18–60 (blue ribbons) from the
solution structure12 of the Sa. typhimurium needle subunit (Protein Data Bank entry 2JOW) were manually docked into the
reconstruction. (b) Side view of the atomic model13 of the Sh. flexneri T3SS needle (Protein Data Bank entry 2V6L), with
one of the protomers shown in green, and (c) top view of this model. (d) The atomic model of the Sh. flexneri T3SS needle in
(b) cut along the plane perpendicular to the helical axis (black line). One of the protomers (green) was aligned with
residues 18–60 of the Sa. typhimurium needle subunit (blue), positioned as fitted to the reconstruction shown in (a). Despite
the difference in symmetry, the paired helices of the needle protomers from both bacteria are located at the same radius
and have the same orientation. (e) The atomic model of the Sh. flexneri T3SS needle in (c) cut along the plane parallel with
the helical axis (black line). It can be seen in this view as well that the paired helices in the models for both bacteria are
located at the same radius and have the same orientation. (f) The reconstruction in (a) cut along the plane parallel with the
helical axis. When the subunit from the atomic model13 of the Sh. flexneri needle (green) is docked into the reconstruction
of the Salmonella needle, its N-terminal part sticks out from the volume (red arrowhead).
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match to the reconstruction and suggests that this is
a better estimate of the resolution. This resolution is
insufficient to determine the absolute hand of the
reconstruction, as the two enantiomorphic volumes
that can be produced are fitted equally well by the
PrgI two-helix bundle that projects out. We have
therefore adopted the same hand (a right-handed 1-
start helix) assumed for the Sh. flexneri needle,4,13
although the hand was not determined for that
needle and was assumed to be the same as that of
the Sa. typhimurium flagellar hook and filament.
The outer diameter of the reconstructed volume is
∼85 Å, and the central lumen has a diameter of
∼25 Å. Docking the two-helix bundle (residues 18–60)
from the center of the PrgI sequence into the
reconstructed volume (Fig. 2a) shows a remarkably
good agreement (Fig. 2d and e) with the corres-
ponding portion of the atomic model13 proposed for
the Sh. flexneri needle. Unfortunately, the limited
resolution of our present reconstruction, combined
with the structural plasticity of the PrgI subunit
outside of the fixed two-helix bundle,12 prevents us
from generating a pseudo-atomic model for the
remainder of the PrgI subunit that must be surround-
ing the lumen. It is quite likely that the residues on the
N-terminal side of the two-helix bundle are involved
in crucial subunit–subunit interactions, as deletion of
the first five residues renders the PrgI subunit
incapable of polymerization.12,15
Discussion
An atomic model of the Sa. typhimurium flagellar
filament5 shows that the lumen in that hollow
assembly is surrounded by coiled coils (D0 domain)
formed by the N-terminus and the C-terminus of the
component subunit. These coiled coils generate 11
nearly vertical protofilaments. The near-atomic
resolution for this system that was achieved by
electron microscopy was possible due to the almost
crystalline order of these filaments. In contrast, we
have observed that the needle from these same
bacteria is quite disordered and structurally hetero-
geneous. The average symmetry that we observe
(∼6.3 subunits/turn of the 26-Å-pitch helix) would
generate 11-start helices with a very short pitch
(∼60 Å). Although we lack the resolution needed to
directly observe the packing of subunits surround-
ing the lumen, the symmetry that exists is incom-
patible with long-pitch 11-start helices. It has
recently been shown that although the Sa. typhimur-
ium flagellar hook protein forms α-helical coiled
coils, the packing of these coiled coils surrounding
the lumen of the hook is very different from the
packing in the flagellar filament, even though the
helical symmetries of both are nearly identical.16 We
have previously shown17 that the flagellin subunits
of Sa. typhimurium and Campylobacter jejuni, while
highly conserved at the sequence level in the D0 and
D1 coiled-coil domains responsible for filament
polymerization in Sa. typhimurium, assemble into
flagellar filaments with very different packing and
helical symmetry. Thus, the ability of the extracel-
lular flagellar and needle proteins to adopt different
packing schemes around the lumens likely reflects
diversity in the physical properties of these different
polymers. While the packing of subunits surround-
ing the lumen of the needle remains unknown, there
is a remarkably good match between the two-helix
bundle that we can fit into our reconstruction and a
model that has been previously proposed for the Sh.
flexneri needle.13
How information about host cell contact is
transmitted to turn on the secretory machinery
located at the base of the T3SS remains a mystery.
The likely role of the needle in transmitting such
information was shown by the fact that mutants of
the needle protein that induce a constitutively “on”
secretion could be found in Shigella.18 However, the
needles formed from the mutant proteins unexpect-
edly showed no overall changes in the average
helical symmetry.6 The structural heterogeneity that
we observe for the Sa. typhimurium needle raises
new possibilities for how the needle might transmit
information about host cell contact. The large
variability in twist present in the Sa. typhimurium
needles means that there must be a correspondingly
large plasticity in how subunits are locally packed
around the lumen. Such plasticity could be used to
transmit information along the needle. A testable
prediction of this hypothesis, beyond the scope of
the present work, is that agents (such as cross-links)
that might lock the needle into a fixed symmetry
should abrogate host cell sensing.
Materials and Methods
Needle complex preparation
To facilitate the formation of elongated needle structures,
we constructed a pWSK29-based plasmid containing prgI,
including a 900-bp upstream region. The plasmid was
transformed into a Sa. typhimurium strain (SB905, described
elsewhere) carrying a plasmid containing an inducible hilA
gene.19 The strain was grown under conditions promoting
formation of the T3SS and induction of the regulatory
protein HilA overnight (LB, 300 mM NaCl, suitable
antibiotics, 0.02% arabinose, 37 °C, and 180 rpm).
Needle complexeswerepurifiedasdescribedpreviously,20
with minor modifications. In brief, cells from a 12-liter
culture volume were harvested, resuspended in 300 ml
of 500 mM sucrose in 150 mM Tris buffer (pH 8.0), and
incubated after the addition of 7.5 ml of 500 mM
ethylenediaminetetraacetic acid (EDTA) solution and
15 ml of lysozyme solution (30 mg/ml, 98,381 IU/mg;
Sigma-Aldrich) on ice for 60 min. Protease inhibitor was
added (three tablets of Complete® Protease Inhibitor;
Roche), and the temperature was raised to 37 °C for
30 min. Successively, 15 ml of 10% lauryldimethylamine
oxide (LDAO), 33 ml of 5 M NaCl, and 9 ml of 1 M
MgCl2 solution were added before the sample was
incubated on ice for 60 min.
Aliquots (28 ml) were transferred into 36-ml ultracen-
trifugation tubes (Sorvall Centrifuges, USA), and a 3-ml
layer of 36% wt/vol CsCl solution [36% wt/vol CsCl in
10 mM Tris, 500 mMNaCl, 5 mM EDTA, and 0.5% LDAO
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(pH 8)] was created below each sample. Solubilized needle
complexes were centrifuged into the lower fractions of the
CsCl cushion (Sorvall Discovery 90SE, rotor AH-629,
28,000 rpm, 5 °C, and 3 h) to avoid pelleting directly onto
the tube wall and damaging the filaments. Fractions
containing needle filaments were pooled, and the density
was adjusted to equal a CsCl concentration of 35–36%wt/
vol. The sample was split into six thinwall tubes (4.4 ml of
PA; Thermo Scientific, USA) and centrifuged overnight
(Sorvall 90SE, rotor TH-660, 40,000 rpm, 12 h, and 5 °C).
The needle complexes formed a visible band in the upper
third of the tube. This fraction was collected and pelleted
(Sorvall RCM150 GX, rotor S100-AT4, 90,000 rpm, 30 min,
and 5 °C). The pellet was resuspended in 10 mM Tris
buffer containing 500 mM NaCl, 5 mM EDTA, and 0.1%
LDAO (pH 8).
Electron microscopy and image processing
A purified needle complex sample was applied to glow-
discharged carbon-coated 400-mesh hexagonal Cu/Pd
grids. For negative-stain images, 5 μl of the sample was
placed on the grid and incubated for 40 s. The grid was
washedand subsequently stainedwith 2%phosphotungstic
acid at neutral pH for 25 s. For cryo-EM, a 5-μl sample was
applied to the glow-discharged grids, the sample was
allowed to settle for 40 s, and excess liquid was removed by
blotting with double-layered filter paper (Whatman 4)
before vitrifying the sample by plunge freezing in liquid
ethane. Low-dose data were collected with a FEI Tecnai
Polara at 300 kV using a Gatan Ultrascan 4000 UHS charge-
coupled device camera (16 megapixels, 4000×4000, 15 μm
pixel size). Images were acquired at a magnification of
112,968× (1.33 Å/pixel at the level of the specimen), with
underfocus values ranging from 1.2 to 3.0 μm. Images were
subsequently decimated to 2.66 Å, and boxes of 120 pixel
length (320 Å) were used for IHRSR.
Scanning transmission electron microscopy
STEM experiments were performed at the Brookaven
National Laboratory using tobacco mosaic virus as
internal standard for mass-per-length measurements.
The preparation of samples and analysis of images were
performed as described previously.11
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